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A poly(lactic-co-glycolic acid) (PLGA) microsphere formulation was 
developed which incorporates carboxylic acid groups into the microsphere surface.  
These functional groups are suitable for coupling to a variety of ligands, and form 
linkages that remain stable in aqueous environments for extended periods of time.  
The ligand binding capacity of these microspheres compares favorably to that of 
comparably sized carboxylated microspheres, which are commonly used as model 
particles for targeted microsphere delivery studies.  The morphology and drug release 
kinetics of this PLGA microsphere formulation are not significantly different from 
those of microspheres made with traditional reagents.  A variety of different protein 
ligands can be conjugated to the surfaces of these microspheres.  These microsphere-
ligand conjugates were then used in model systems to evaluate the effect of conjugated 
ligands on microsphere behavior.  Microsphere retention in agarose columns was 
increased by ligands on the microsphere surface specific for receptors on the agarose 
matrix.  In another experiment, conjugating the ligand Ulex europaeus agglutinin 1 to 
the microsphere surface increased the adhesion of microspheres to Caco-2 monolayers 
compared to control microspheres.  This increase in microsphere adhesion was 
negated by co-administration of L-fucose, indicating that the increase in adhesion is 
due to specific interaction of the ligand with carbohydrate receptors on the cell 
surface.  These results demonstrate that the ligands conjugated to the microspheres 
maintain their receptor binding activity, and are present on the microsphere surface at  
a density sufficient to target the microspheres to both monolayers and three-
dimensional matrices bearing complimentary receptors.  These microspheres combine 
the capability to target specific cell types through surface-conjugated receptors with 
the ability to release encapsulated drugs over extended periods of time.  This 
combination of properties enhances the utility of biodegradable microspheres for a 
variety of drug delivery applications. 
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CHAPTER 1 
INTRODUCTION* 
 
1.1  Biodegradable microspheres for drug delivery 
  Over the past 25 years, biodegradable polymer microspheres have been 
investigated for a wide variety of drug delivery applications, including but not limited 
to vaccines [1], tumor treatment [2], drug delivery to the retina [3], and control of 
inflammation [4].  Entrapment of drugs within microspheres provides many 
advantages compared to more traditional drug formulations.  The microspheres release 
encapsulated molecules over extended time intervals, from days to several months.  
Release rates can be modified by adjustment of microsphere physical properties such 
as polymer molecular weight, monomer composition, and microsphere size.  
Microspheres provide a dry, stable environment for encapsulated molecules, extending 
the shelf life of the drug and making refrigerated storage less critical.  The 
microspheres continue to protect the encapsulated agent after administration, 
permitting delivery by routes that might otherwise not be feasible. For example, 
microspheres can be used to orally administer agents that might be degraded by 
exposure to acid or digestive enzymes in the upper gastrointestinal tract. 
  The most commonly used polymer in biodegradable microsphere formulations 
is PLGA.  The lactic and glycolic acid monomer units of PLGA are linked by ester 
bonds (Figure 1.1).  Degradation of PLGA occurs by hydrolysis of these ester bonds, 
leading to a decrease in molecular weight of the polymer.  This degradation occurs 
throughout the volume of the microspheres, and is called bulk erosion.  The 
microspheres maintain their structure during degradation, until PLGA oligomers 
 
 
* Sections of this chapter originally appeared in Keegan, M. E.; Whittum-Hudson, J. 
A.; Saltzman, W. M. Biomaterials 2003, 24, 4435-4443. 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  Structure of PLGA.  Lactic acid (x) and glycolic acid (y) groups are linked 
in random order by ester bonds.  Relative monomer composition (ratio of x to y) can 
be adjusted as desired during polymerization. 
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become short enough that they become soluble in the surrounding aqueous 
environment.  At this point, the microspheres begin to physically break apart.  
Degradation of the PLGA oligomers continues until these oligomers are completely 
hydrolyzed to lactic and glycolic acid monomer units.  These nontoxic monomers are 
found naturally in cells as part of normal cell metabolism, eventually being 
metabolized to carbon dioxide and water [5], which is a significant advantage to using 
PLGA for biomedical applications such as drug delivery in which biocompatibility of 
the material is crucial. 
 
1.2  Targeting microspheres to specific cells 
  Biodegradable microspheres are of interest in many applications in part 
because they allow for localized delivery of the encapsulated agent directly to the 
desired site.  Delivering therapeutic agents directly to the site of interest instead of 
systemically can result in lower required doses to achieve the desired effect, which has 
advantages in terms of both cost savings and reduction of potential unwanted side 
effects.  Often this site specificity comes from direct physical administration of the 
microspheres at the site of interest (such as injection into the center or periphery of 
tumors) [6].  Oral or intravenous administration of the microspheres is simpler, but 
with the trade off of loss of site specificity.  Efforts to solve the problem of 
maintaining site specificity for microspheres delivered by mucosal or intravenous 
routes involve modifying the surface properties of the microspheres to increase their 
bioadhesiveness to desired tissues [7], through changes to microsphere properties and 
addition of surface ligands which bind to receptors on the surface of targeted cells. 
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1.2.1  Targeting by nonspecific methods 
  Physicochemical properties of microspheres influence their interactions with 
tissues.  For example, negatively charged microspheres have reduced uptake in the 
intestine compared to non-ionic microspheres [8].  This result is not surprising 
considering that the intestinal epithelial lining is also negatively charged, due at least 
in part to terminal sialic acid groups on side chains of secreted mucins and membrane-
bound glycoproteins [9].  The permeability of microspheres through (negatively 
charged) gastric mucus decreases as the ζ-potential of the microspheres becomes 
increasingly negative [10]. 
  In addition to the effect of surface charge, the hydrophobicity of microspheres 
also affects their interactions with tissues.  Intestinal uptake studies with PLGA and 
polystyrene microspheres show that the more hydrophobic polystyrene microspheres 
have a much higher level of uptake [11,12].  The correlation of particle uptake with 
hydrophobicity was verified with a panel of microspheres made of various polymers 
with significantly different hydrophobicities [11].  For nasal administration, however, 
microspheres made of a PLA-PEG diblock copolymer demonstrated an approximately 
10-fold increase in uptake into the circulation and 4-fold increased uptake into lymph 
nodes in rats compared to microspheres of PLA [13].  Incorporation of PEG into the 
formulation makes the microspheres more hydrophilic, so this result runs counter to 
the findings for uptake in the intestine and suggests that microsphere physicochemical 
properties need to be optimized for the particular delivery route being considered. 
  For microspheres delivered intravenously, incorporating PEG into the 
formulation increases the circulation time of the microspheres [14,15].  Clearance of 
micro- and nanospheres from the systemic circulation by the liver and spleen can 
interfere with effective use of these vehicles for sustained-release drug delivery in the 
bloodstream.  Contrary to the efforts to target microspheres to specific cells or tissues, 5 
 
using PEG to reduce the clearance rate is an “anti-targeting” application, in which 
microsphere interactions with tissues are undesirable and microsphere properties are 
altered to minimize those interactions.  The effects of changes to microsphere 
physicochemical properties on their interactions with cells and tissues are limited in 
specificity.  Efforts to optimize these properties for a given application are best suited 
to situations in which the goal is a general increase (or decrease) in microsphere 
adherence or uptake without regard for any specific cell types. 
 
1.2.2  Targeting by specific ligands on the microsphere surface 
  Beyond the general tissue targeting effects that can be achieved by altering 
microsphere physicochemical properties, site specific targeting can be achieved 
through ligand-receptor interactions.  By labeling the surface of microspheres with 
appropriate ligands, surface receptors on selected cell types can be targeted.  When the 
microspheres encounter cells expressing the correct surface receptors, binding of the 
receptors to ligands on the microsphere surface will cause retention of the microsphere 
at the cell surface.  This strategy is being investigated for a number of different 
applications, including tumor targeting [16] and increasing uptake of drugs into the 
circulation by adhesion of microspheres to enterocytes of the intestinal epithelium 
[17,18].  A more sophisticated application of ligand-receptor targeting of microspheres 
involves mimicry of the rolling and firm adhesion behavior demonstrated by 
leukocytes when they encounter sites of inflammation in the systemic circulation [19].  
Microspheres with surface-bound sialyl Lewis X antigen were evaluated in parallel-
plate flow chambers coated with P- and E-selectin, which are expressed by vascular 
endothelial cells as part of the inflammatory response.  Rolling velocity of the 
microspheres in the flow chamber decreased with increasing density of conjugated 
sialyl Lewis X antigen [20]. 6 
 
  The concept of using specific ligand-receptor binding interactions to target 
microspheres to specific cell types draws support from observations of pathogen 
interactions with cells of the intestinal epithelium.  Sampling of intestinal contents for 
presentation to the immune system is performed by M cells, which are specialized 
epithelial cells capable of taking up particles.  M cells are present in the epithelium 
overlying lymphoid follicles, and transcytose particles rapidly from the intestinal 
lumen to the underlying lymphoid tissue [21].  A variety of different pathogens, both 
viral and bacterial, have the ability to target and selectively bind to M cells in the gut 
[22].  This targeting is accomplished by interactions of ligands on the pathogen 
surfaces with receptors on the apical surface of the M cells.  The pathogens take 
advantage of the particle uptake behavior of the M cells to penetrate the epithelial 
lining of the intestine and initiate infection.  It is important to note that the short list of 
licensed oral vaccines includes the Sabin attenuated oral polio vaccine as well as an 
attenuated Salmonella typhi vaccine.  These pathogens are among those with 
demonstrated ability to target M cells [23,24].  This observation suggests that the 
addition of appropriate ligands to the surface of microspheres would significantly 
increase the effectiveness of orally administered vaccines encapsulated in 
microspheres. 
 
1.3  Increasing vaccine delivery to M cells – an application of microsphere targeting 
  A number of studies in animal models have demonstrated that oral delivery of 
antigen-containing microspheres leads to both systemic and mucosal immune 
responses (Table 1.1).  These immune responses, however, are typically much lower 
in strength than those obtained by injection of microspheres, and require much larger 
doses of antigen.  The difference in dose and effectiveness is vast: one investigator has 
summarized the difference by remarking that a 100-fold increase in the oral dose will 7 
 
 
 
Table 1.1.  Mucosal and Systemic Immune Responses 
to Orally Delivered Microsphere Vaccines 
 
Antigen(s) Antigen  dose  and 
schedule 
Observed immune 
response 
Ref. Notes 
Ovalbumin  Six 100 µg doses 
over 10 days 
 
Systemic CTL 
Intestinal IgA 
[25]  
  250 µg/day for 3 
days; single 250 µg 
booster at 4 weeks 
 
Intestinal IgA 
Serum IgG 
 
[26]  
  1 mg/day for 3 
days; repeated 4 
weeks later 
Salivary IgA 
Vaginal IgA 
Intestinal IgA 
Serum IgG, IgA 
 
[27]  Expands on similar 
findings in [28] 
Influenza 
vaccine 
Single 70 µg dose  Salivary IgA 
Intestinal IgA 
 
[29]  
Bordetella 
pertussis 
Single 10 µg dose 
of fimbriae 
Serum IgM, IgG, IgA 
Salivary IgA, IgG 
Fecal IgA, IgG 
Vaginal IgG 
[30]  >95% reduction in 
viable bacteria 
after intranasal 
challenge compard 
to unimmunized 
controls 
 
  Three 100 µg doses 
of pertussis toxoid 
and filamentous 
haemagglutinin 
over 8 weeks 
Serum IgG, IgA  [31]  Complete 
clearance of 
bacteria 14 days 
after intranasal 
challenge 
 
Yersinia 
pestis V and 
F1 antigens 
3.0 µg V antigen 
0.47 µg F1 antigen 
in single dose 
Serum IgG 
Intestinal IgA 
Bronchial IgG 
[32] Intranasal  booster 
significantly 
enhanced anti-V 
antigen response 
 
Anti-idiotype 
to chlamydial 
exoglycolipid 
antigen 
Two 4 µg doses 
over 2-3 weeks 
Serum neutralizing 
antibody 
[33]  Up to 90% 
reduction in 
infectious yield 
after challenge 
compared to 
controls 
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produce a 100-fold smaller immune response in comparison to an injected dose of the 
same microspheres [34]. 
  So while vaccines made with biodegradable microspheres have been shown to 
be capable of generating immune responses, the low efficiency of these particles when 
delivered orally remains a challenge.  This is underscored by the results of a human 
trial in which antigens of enterotoxigenic Escherichia coli were encapsulated in PLGA 
and then administered by intestinal tube.  Despite receiving 4 large (1 mg) doses of the 
encapsulated antigen over a 4-week period, only 30% of the volunteers were protected 
from a subsequent E. coli challenge [35].  A principal cause of the low efficiency of 
orally administered microsphere vaccine formulations is thought to be poor uptake of 
the particles by the relevant tissues of the intestine.  If this is the case, mimicking the 
behavior of pathogens with M cell targeting ligands could increase uptake efficiency 
and lead to improved immune responses to vaccines encapsulated in microspheres. 
  The first step in targeting microspheres to M cells (or any other cell type) is 
identification of ligands that bind specifically to the selected cells.  The lectin UEA 1 
binds to mouse M cells, but not enterocytes or mucus-secreting goblet cells [36].  To 
test the effect of lectin-mediated targeting, UEA 1 has been conjugated to liposomes 
which were then delivered orally [37] or administered directly to the small intestine 
[38] of mice.  Addition of the lectin increased the uptake of these liposomes by 
approximately three-fold compared to untargeted liposomes.  UEA 1 conjugated to the 
surface of carboxylated polystyrene microspheres increased microsphere uptake after 
oral delivery to mice by nearly 100-fold [39].  Most ligand-M cell specific binding 
interactions appear to be species-specific, however, and no lectin has been found to 
date that binds specifically to human M cells but not to regular enterocytes.  Screening 
of various ligands has indicated, however, that human M cells preferentially express 9 
 
the sialyl Lewis A antigen, as determined by binding of a monoclonal antibody 
specific for this antigen to explants of human intestinal tissue [40]. 
  Microspheres coated with secretory IgA have roughly 20-fold increased uptake 
in mice relative to microspheres coated with BSA [41].  M cells have been shown to 
selectively bind IgG and IgA, irrespective of the antigen specificity of the 
immunoglobulin molecule [42].  Unlike lectin-M cell binding, this antibody selectivity 
is not species-specific, as human secretory IgA was shown to increase particle uptake 
in mice [41] and a mouse monoclonal IgA demonstrated binding selectivity for M 
cells in the intestinal epithelia of not only mice but also rats and rabbits [42].  
  Even if appropriate ligands can be identified and conjugated to the surface of 
microspheres, potential obstacles to effective targeting need to be overcome.  
Although many of these obstacles apply to just about any in vivo targeting scenario, 
the particular application of targeting vaccines to M cells provides an opportunity to 
illustrate a number of them.  A variety of events can occur either during preparation or 
after administration of targeted oral microsphere vaccines that could interfere with 
targeting of the microspheres to M cells (Figure 1.2).  First, the linkages between 
targeting molecules and the microspheres must remain intact until the microspheres 
reach their target (Figure 1.2B).  The acidic environment of the stomach is of 
particular concern in this regard for M cell targeting, as the degradation of PLGA is 
acid-catalyzed.  The premature release of targeting molecules is significant not only 
because the released molecules can no longer bind the microspheres to their target, but 
also because they will serve as targeting inhibitors, by competing for binding sites 
with targeting molecules still bound to microspheres. In one investigation of the 
release of surface bound lectin from microspheres into HEPES buffer at 4°C, after 21 
days less than 10% of the lectin had been released from the microspheres [17].  The 
effect of exposure to acid on release of surface-conjugated molecules, however,  10 
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Figure 1.2.  Obstacles to M cell targeting.  A: Successful targeting of M cell receptors.  
B: Premature release of targeting ligand.  C: Enzymatic degradation of targeting 
ligand.  D: Microsphere-ligand coupling near ligand binding site.  E: Antibody 
response to targeting ligand.  E = Enterocyte; L = Lymphocyte; M = M cell.  11 
 
remains to be determined.  Should microsphere degradation due to stomach acidity 
prove to be a problem, the solution might be as simple as co-administration of an 
appropriate buffer with the microspheres. 
  Not only does the linkage between targeting molecule and microsphere need to 
remain stable, but the selected targeting molecules must also be resistant to 
degradation in their in vivo environment (Figure 1.2C).  The need to protect proteins 
from rapid degradation in the digestive tract, for example, is a primary reason why 
encapsulating vaccines within microspheres is desirable; surface-conjugated proteins 
however, will not enjoy this same protection.  Lectins display good resistance to 
degradation [43], but other potential targeting molecules (such as the monoclonal 
specific to sialyl Lewis A antigen) remain unproven in this regard.  Secretory IgA may 
prove effective as a stable M cell targeting molecule; dimeric IgA coupled to secretory 
component demonstrates good resistance to degradation in the intestinal lumen [44].  
Other molecules that should demonstrate suitable resistance to degradation are the 
targeting ligands used by pathogens to selectively bind to M cells.  A subunit of 
invasin, an outer membrane protein of Yersinia pseudotuberculosis, was produced in 
E. coli culture, purified, and coupled to functionalized polystyrene microspheres.  
These targeted microspheres showed a six-fold increase in uptake into the systemic 
circulation compared to controls after oral administration to rats [45].  Future work to 
identify, isolate, and produce in culture the M cell targeting ligands of other pathogens 
could provide a library of gastrointestinal tract-stable molecules that could be used to 
direct vaccine-carrying microspheres to M cells. 
  Depending on the functional groups present on the surface of the microspheres, 
a number of different conjugation schemes can be employed for linking ligands to 
microspheres.  These different schemes use different functional groups on the ligand 
molecule.  Different conjugation schemes may prove optimal for different targeting 12 
 
molecules, depending on what functional groups are present in or around the receptor 
binding region of the targeting ligand.  The method by which targeting ligands are 
fixed to the microspheres must not disrupt the ability of the ligand to bind to its target 
receptor.  If the targeting molecule is conjugated to the microsphere at a site close to 
the receptor binding region, steric hindrance could prevent interaction between the 
targeting molecule and cells being targeted (Figure 1.2D). 
  Beyond factors related to the means by which targeting molecules are fixed to 
the microspheres, another issue that will require investigation is the potential for 
immune responses to be generated against the targeting molecules themselves (Figure 
1.2E).  For M cell targeting, the presence in the gut of antibodies specific for targeting 
ligands could neutralize the targeting ability of the microspheres.  Intestinal antibody 
interference with vaccine immunogenicity has been observed clinically with the S. 
typhi strain Ty21a oral vaccine [46].  The potential for a similar anti-targeting ligand 
response would be of particular concern for any oral vaccine regimen requiring 
multiple administrations of microspheres using the same targeting ligand.  Mice 
generate a mild anti-UEA 1 response when the lectin is orally delivered, for example 
[47], although at this point it remains unclear just how strong a mucosal anti-M cell 
ligand response would be required to interfere with targeting of subsequent doses of 
microspheres using that same ligand.  Different targeting ligands would be likely to 
provoke immune responses of varying intensity.  Of the current targeting ligands 
being investigated, human secretory IgA should be the most suitable for use in 
repeated administrations, as it is normally present in the intestinal lumen and should 
therefore be well-tolerated by the immune system as a native protein.   
 13 
 
1.4  Increasing capacity for surface ligands on PLGA microspheres 
  Understanding the process by which PLGA microspheres are produced is 
critical to efforts to increase the microsphere surface capacity for conjugated ligands.  
Microsphere properties depend on a variety of processing variables, providing a 
number of opportunities to alter production to create microspheres with the desired 
characteristics. 
 
1.4.1  Microsphere production by the double-emulsion method 
  PLGA microspheres are commonly fabricated by an emulsion method.  This 
technique is straightforward and adaptable for encapsulating molecules with a range of 
physical properties.  For encapsulating hydrophilic molecules such as proteins, a 
double emulsion technique is used, as summarized in Figure 1.3.  First, PLGA is 
dissolved in an appropriate organic solvent, such as dichloromethane.  Added to this 
polymer solution is the molecule to be encapsulated, in aqueous solution.  The volume 
of the aqueous phase should be as small as possible, ideally no more than 10% of the 
volume of the PLGA solution.  The two phases are then emulsified, by either high 
shear mixing or sonication.  The resulting primary emulsion contains small droplets of 
the aqueous drug solution within the organic PLGA solution.  Next, an aqueous 
surfactant solution (most commonly PVA) is added to the primary emulsion.  The 
volume of the surfactant solution should be at least twice as great as the volume of the 
organic phase, but small enough that the total volume can be rapidly processed by the 
equipment used for emulsification.  The mixture is then emulsified again, to create the 
secondary emulsion.  This emulsion contains two dispersed phases, with the inner 
dispersed phase consisting of droplets of the molecule to be encapsulated.  The inner 
dispersed phase is contained within the outer dispersed phase, which is the organic 
PLGA solution.  The outer dispersed phase exists as droplets in the continuous phase  14 
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of the aqueous surfactant solution.  Surfactant molecules partition at the interface of 
the continuous phase and outer dispersed phase, with hydrophilic regions in the 
continuous phase and hydrophobic regions in the dispersed phase.  The surfactant 
molecules prevent coalescence of the emulsified droplets of the organic phase. 
  The emulsion is quickly transferred to a large volume of aqueous surfactant 
solution, which is rapidly stirred to disperse the droplets of the organic phase.  The 
volume of surfactant solution used is enough to fully dissolve the organic solvent, and 
therefore depends on the solubility of the organic solvent in water.  For 
dichloromethane, which is soluble in water up to approximately 2% [48], 100 ml of 
stirring surfactant solution is used for every 2 ml dichloromethane.  When the 
emulsion is transferred to the stirring surfactant solution, the organic solvent droplets 
rapidly dissolve into the solution.  The water-insoluble PLGA precipitates out of 
solution, forming microspheres in the place of dissolving organic phase droplets and 
entrapping the molecules of the inner dispersed phase.  The newly formed 
microspheres are stirred for several hours to evaporate away the organic solvent, are 
washed several times with water, and then lyophilized to form a free-flowing dry 
powder. 
  To encapsulate hydrophobic compounds into PLGA microspheres, the 
compound of interest is simply dissolved directly into the initial organic PLGA 
solution.  Only one emulsification is performed, creating a dispersed organic phase 
containing PLGA and the molecule to be encapsulated within the continuous aqueous 
phase of the surfactant solution.  After this emulsification, processing continues 
identically to the double-emulsion method. 
 16 
 
1.4.2  Current methods for affixing ligands to the surface of PLGA microspheres 
  Most studies of particle targeting to cells by specific ligands have avoided the 
use of biodegradable polymer microspheres.  Functionalized polystyrene microspheres 
are commercially available, with well-established protocols for coupling molecules to 
their surfaces.  Similarly, liposomes can be formulated from molecules with a variety 
of different reactive groups suitable for coupling to targeting ligands.  Reports of 
chemical coupling to PLA or PLGA microspheres, however, are much less prevalent.  
The commonly used forms of these polymers are chemically (and biologically) inert, 
with the exception of the degradation reaction.  This inertness is a desirable property 
from a biocompatibility standpoint, but complicates attempts to chemically couple 
molecules to PLGA microspheres.  Furthermore, coupling reactions must be 
performed under conditions designed to minimize premature degradation of the 
microspheres and their contents. 
  Despite the difficulties associated with conjugating molecules to the surface of 
biodegradable microspheres, recent reports indicate that there are a number of ways by 
which it can be accomplished.  For example, spray dried microspheres made of 
PLGA-COOH [49] have had lectins conjugated to their surface by carbodiimide 
conjugation [17].  This conjugation was achieved by amide bond formation between 
PLGA carboxylic acid groups and primary amines present on the lectins.   
Direct coupling to PLGA carboxylic acid end groups may not be possible, 
however, for microspheres made by emulsion methods.  Microspheres produced by 
emulsion methods have surface layers of surfactant molecules.  During microsphere 
formation, as organic solvent dissolves out of droplets into the continuous phase, 
PLGA precipitating out of solution entraps surfactant molecules present at the 
interface between the continuous and organic dispersed phases.  The hydrophilic 
portion of the surfactant does not partition into the organic phase, and is therefore left 17 
 
exposed at the microsphere surface.  When PVA is used as the surfactant, the result is 
microspheres with surface hydroxyl groups, which are present as side groups on PVA 
chains (Figure 1.4).  This surfactant layer remains at the microsphere surface even 
after repeated water washing of the microspheres [50], and provides a steric barrier 
which may interfere with successful conjugation of ligands to PLGA-COOH in the 
microsphere core.  In this situation, glutaraldehyde can be used to conjugate proteins 
to PVA hydroxyl groups present on the surface of microspheres [51]. 
Another method for coupling ligands to PLGA takes advantage of biotin-
avidin interactions.  Copolymers of PLA-PEG were produced which have biotin 
molecules conjugated to the ends of the polymer chains.  This copolymer was used to 
produce nanospheres with biotin groups at the surface [52].  The nanospheres were 
then incubated with avidin, which exhibits strong, multivalent binding with biotin.  
Nanospheres were then incubated with biotinylated lectins, which was bound to the 
avidin present at the microsphere surface.  In a similar method, PLGA microspheres 
can be incubated with copolymers of poly(L-lysine)-PEG-biotin [53].  The positive 
charge of the copolymer causes adsorption to the microsphere surface, which can be 
followed by incubation with avidin and biotinylated ligands as described above. 
 
1.4.3  A novel PLGA microsphere formulation with a high density of surface 
carboxylic acid groups 
  The majority of studies performed to date using surface-conjugated ligands to 
target microspheres to tissues used carboxylated polystyrene microspheres [18,39,54-
56].  These microspheres are ideal model particles because they have a high density of 
surface carboxylic acid groups at the microsphere surface, enabling a high level of 
surface ligand conjugation.  Carboxylic acid groups can be linked to primary amines 
by use of carbodiimide cross-linkers by well-established protocols [57].  Carbodiimide  18 
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Figure 1.4.  Use of PVA in microsphere production.  A: Structure of PVA molecule.  
Groups with hydroxyl side chains (x) typically comprise from 88 to 100% of the 
monomer units.  B: Stabilizing the microsphere emulsion with PVA results in 
microspheres with surface hydroxyl groups  19 
 
conjugation is a two-step process, in which the carboxylic acid groups are first 
activated for cross-linking, followed by exposure to the primary amine-bearing 
compound and subsequent amide bond formation.  The stepwise nature of this 
protocol and the chemistry of carbodiimides limits reactions to the desired carboxylic 
and amine functional groups.  This is a substantial advantage of this cross-linking 
scheme compared to other cross-linking agents such as glutaraldehyde, which reacts 
with a variety of different chemical groups and therefore increases the chances of 
altering the structure of conjugated ligands at locations critical to their binding 
activity.  Carbodiimide chemistry is also popular for biomolecule conjugation because 
all the processing steps take place in aqueous buffers, unreacted cross-linker degrades 
in water in a period of hours, and the amide linkages that are formed have good long-
term stability in water.  But while carboxylated polystyrene microspheres are ideal for 
ligand conjugation, these nondegradable particles are unsuitable for drug delivery. 
  PLGA microspheres with carboxylic acid groups at their surfaces would 
combine the ability to conjugate ligands to the microspheres by carbodiimide 
chemistry with a controlled release delivery vehicle of clinical relevance.  In selecting 
a method for introducing carboxylic acid groups at the surface of PLGA microspheres 
consideration must by given to minimizing changes to other microsphere properties.  
Replacing the stabilizer PVA with a surfactant that has carboxylic acid side chains 
results in PLGA microspheres with surface carboxylic acid groups.  PEMA is such a 
surfactant, which is structurally similar to PVA (Figure 1.5A) with the exception that 
PEMA has carboxylic acid side groups instead of hydroxyl side groups.  Both 
surfactants are water-soluble polymers with backbones of carbon-carbon bonds and 
side chains of hydrophilic groups.  PLGA microspheres made with PEMA as the 
stabilizer (PLGA/PEMA microspheres) (Figure 1.5B) achieve the goal of creating a 
biodegradable microsphere formulation with surface carboxylic acid groups while  20 
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Figure 1.5.  Replacing PVA with PEMA for microsphere production.  A: Structure of 
PEMA molecule.  B: Using PEMA as the stabilizer produces microspheres with 
surface carboxylic acid groups. 21 
 
making no other significant changes to the microsphere fabrication method.  This 
dissertation describes studies comparing PLGA/PEMA microspheres to other PLGA 
microsphere formulations, including the relative capacity of these microspheres for 
ligands conjugated to the surface by carbodiimide chemistry (Figure 1.6).  The effect 
of surface-bound ligands on microsphere behavior in both in vitro and in vivo model 
systems is also evaluated.   22 
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CHAPTER 2 
PLGA MICROSPHERES WITH SURFACE CARBOXYLIC ACID GROUPS 
  
2.1  Production of PLGA microspheres 
  Microspheres were prepared using the double-emulsion technique described in 
section 1.4.1, using PLGA with a 50:50 lactide:glycolide ratio and an inherent 
viscosity of 0.59 dL/g in hexafluoroisopropanol, and PLGA-COOH with a 50:50 
lactide:glycolide ratio and an inherent viscosity of 0.32 dL/g in chloroform 
(Birmingham Polymers, Birmingham, AL).  Four hundred milligrams of PLGA or 
PLGA-COOH was dissolved in 2 ml dichloromethane in a glass tube.  One hundred 
microliters of a 75 mg/ml solution of FITC-BSA (Sigma, St. Louis, MO) in water was 
added to the polymer solution while gently vortexing the tube.  For microspheres with 
no encapsulated protein, 100 µl of Milli-Q water instead of FITC-BSA solution was 
added to the polymer solution.  The polymer solution was then sonicated for 15 s at 
40% amplitude with a TMX 400 sonic disruptor (Tekmar, Cincinnati, OH), to create 
the primary emulsion.  Four milliliters of an aqueous 1% w/v solution of either PVA 
(Sigma) or PEMA (Polysciences, Warrington, PA) was added to the tube and the 
sonication step was repeated.  Immediately after the second sonication, the emulsion 
was poured into 100 ml of 0.3% w/v aqueous solution of the same stabilizer used for 
the second emulsion, under rapid stirring with a magnetic stirrer.  The resulting 
microspheres were stirred in this solution for 3 hours in order to evaporate away the 
dichloromethane.  The microspheres were then washed 3 times, by centrifuging at 
10,000x g for 10 minutes at 4°C and replacement of the supernatant with fresh Milli-Q 
water.  Following the washes, microspheres were resuspended in 4 ml Milli-Q water 
and lyophilized to dryness.   
 24 
 
2.2  Comparison of morphology of different microsphere formulations 
Microspheres were fixed to aluminum sample stubs with double-sided carbon 
tape, and sputter coated with gold for viewing by scanning electron microscopy.  
Micrographs were analyzed with Scion Image software (Scion Corporation, Frederick, 
MD) to determine size distributions of different microsphere samples.   
  Switching from PVA to PEMA as the stabilizer for PLGA microsphere 
production did not noticeably change microsphere morphology.  Both PLGA/PVA and 
PLGA/PEMA microsphere types exhibited smooth, unbroken surfaces (Figure 2.1), 
and nearly identical size distributions (Figure 2.2), with a mean diameter of 686 nm 
for PLGA/PVA, and 682 nm for PLGA/PEMA.  The PLGA-COOH/PVA 
microspheres also had smooth, unbroken surfaces, but were noticeably smaller, with a 
mean diameter of only 361 nm. During PLGA-COOH/PVA microsphere production, 
undissolved polymer was found in the tube after the sonication steps.  Microsphere 
yield calculations indicated that the PLGA-COOH had only dissolved to a 
concentration of approximately 150 mg/ml dichloromethane, compared to the 200 
mg/ml used for making both PLGA/PVA and PLGA/PEMA microspheres.  With this 
reduced polymer concentration comes a reduction in solution viscosity, resulting in 
more effective droplet dispersion during the sonication steps, and therefore smaller 
microspheres [58]. 
  The presence of encapsulated protein did not significantly effect the size of 
PLGA/PEMA microspheres.  Microspheres with encapsulated FITC-BSA (Figure 
2.3A) have the same smooth, unbroken surfaces as microspheres with no encapsulated 
protein (Figure 2.1B).  The size distributions are also very similar (Figure 2.3B), with 
the presence of FITC-BSA slightly increasing the mean microsphere diameter, from 
682 nm to 813 nm. 25 
 
 
 
 
 
Figure 2.1.  Scanning electron micrographs of (A) PLGA/PVA, (B) PLGA/PEMA, 
and (C) PLGA-COOH/PVA microspheres with no encapsulated protein. 26 
 
 
 
 
 
 
 
 
 
 
 
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0 0.5 1 1.5 2 2.5 3
Microsphere Size (µm)
R
e
l
a
t
i
v
e
 
F
r
e
q
u
e
n
c
y
PLGA/PVA
PLGA/PEMA
PLGA-COOH/PVA
 
 
 
 
Figure 2.2.  Microsphere size distributions (n = 3246 for PLGA/PVA, 2605 for 
PLGA/PEMA, 3246 for PLGA-COOH/PVA).  Microspheres have no encapsulated 
protein. 27 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  PLGA/PEMA microspheres with encapsulated FITC-BSA.   
A: Microsphere morphology.  B: Effect of encapsulated protein on size distribution of 
PLGA/PEMA microspheres (n = 2083 for FITC-BSA encapsulated microspheres, 
2605 for microspheres with no encapsulated protein). 
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2.3 Conjugation of ligands to microspheres 
The technique used to conjugate ligands to the microsphere surfaces is a 
slightly modified version of a manufacturer’s protocol for protein conjugation to 
carboxylated polystyrene microspheres (Polysciences Technical Data Sheet 238C).  
Microspheres of PLGA/PVA, PLGA/PEMA, PLGA-COOH/PVA, and carboxylated 
polystyrene (Polysciences, diameter 0.792 ±0.023 µm) were washed twice with 0.1 M 
sodium bicarbonate buffer, pH adjusted to 9.0.  The microspheres were then washed 3 
times with 0.02 M sodium phosphate buffer, pH = 4.8.  After washing, the 
microspheres were resuspended to 20 mg/ml in phosphate buffer and then diluted 
down to 10 mg/ml with 2% w/v EDC (Sigma) in phosphate buffer.  This suspension 
was incubated for 3 hours at 25°C on an end-to-end shaker to activate carboxylic acid 
groups.  After incubation, microspheres were washed 3 times in phosphate buffer, and 
resuspended to 10 mg/ml in borate buffer (0.2 M boric acid, pH adjusted to 8.5) with 
80 µg/ml of the primary amine-bearing model ligand 5-(aminoacetamido)fluorescein 
(Molecular Probes, Eugene, OR).  Microspheres were incubated with ligand overnight 
at 25°C on an end-to-end shaker.  Microspheres were then centrifuged at 10,000x g for 
5 minutes, and the supernatant was removed.  The microspheres were resuspended to 
10 mg/ml in borate buffer, and 4 µl of 0.25 M ethanolamine in borate buffer was 
added for each milligram of microspheres.  Microspheres were incubated for 30 
minutes at 25°C to quench any unreacted sites, and then washed twice with Milli-Q 
water, resuspended in 4 ml Milli-Q water, and lyophilized to dryness.   
The conjugation protocol was also performed with PLGA/PEMA microspheres 
using the proteins HSA and hIgA (both from Sigma) as ligands, at a concentration of 
320 µg/ml during ligand incubation with the microspheres.   29 
 
The conjugation process did not change microsphere morphology, as shown in 
the scanning electron micrograph in Figure 2.4.  Microsphere surfaces remained 
smooth and unbroken. 
 
2.4  Detection of conjugated ligands 
  Conjugation of 5-(aminoacetamido)fluorescein to the surface of PLGA/PEMA 
microspheres was verified by fluorescence microscopy, using a Zeiss Axiovert 200 
inverted microscope (Thornwood, NY) with fluorescent filters.  Figure 2.5D shows the 
presence of the fluorescent ligand on PLGA/PEMA microspheres.  Neither adsorption 
of the ligand to PLGA/PEMA microspheres (Figure 2.3F) or conjugation of the ligand 
to PLGA/PVA microspheres was detected by microscopy (Figure 2.5B).  A more 
quantitative analysis of 5-(aminoacetamido)fluorescein coupling to the surface of the 
microspheres was performed by flow cytometry (FACScalibur, Becton Dickinson, San 
Jose, CA).  Fluorescence intensity of PLGA/PEMA microspheres before and after 
both ligand conjugation and adsorption is shown in Figure 2.6.  These dot plots show 
substantial conjugation of ligand to the microspheres (Figure 2.6B).  A slight increase 
in fluorescence is also observed after adsorption of the fluorescent ligand to the 
microspheres (Figure 2.6C).  Samples of all 4 microsphere formulations with  
5-(aminoacetamido)fluorescein conjugated or adsorbed to the surface were analyzed 
by flow cytometry, and the mean fluorescence intensity was determined for each 
sample (Figure 2.7).  PLGA/PEMA and carboxylated polystyrene microspheres had 
comparable fluorescence intensities after ligand conjugation.  PLGA/PVA and PLGA-
COOH/PVA microspheres had only low levels of ligand conjugation, with the PLGA-
COOH/PVA microspheres showing slightly more fluorescence (Figure 2.7, inset).  
This fluorescence is likely due to ligand conjugation to carboxylic acid groups at the 
ends of PLGA chains.  Ligand conjugation is clearly more effective with  30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.  Scanning electron micrograph of PLGA/PEMA microspheres after 
conjugation to 5-(aminoacetamido)fluorescein. 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Transmission (A, C, E) and fluorescence (B, D, F) micrographs of PLGA 
microspheres after conjugation to 5-(aminoacetamido)fluorescein.  A, B: PLGA/PVA 
microspheres with conjugated ligand.  C, D: PLGA/PEMA microspheres with 
conjugated ligand.  E, F: PLGA/PEMA microspheres with adsorbed ligand. 
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Figure 2.7.  Comparison of capacity for coupling of 5-(aminoacetamido)fluorescein to 
the surface of various microsphere formulations.  Data are the mean fluorescence 
measurement for microspheres as analyzed by flow cytometry.  Inset: fluorescence 
intensity of PLGA/PVA and PLGA-COOH/PVA microspheres.  Data are mean ± 
standard deviation of mean fluorescence intensity for 3 separate conjugations or 
adsorptions of ligand to each sphere type. 
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PLGA/PEMA microspheres, although whether this is because the acid end groups of 
the PLGA-COOH/PVA microspheres are being shielded by PVA or are simply present 
in lower numbers than on PLGA/PEMA microspheres remains unclear. 
For microspheres with protein conjugated to the surface, aliquots of 
microspheres were suspended at 5 mg/ml in a 1:500 dilution in PBS of mouse IgG 
specific for HSA (Sigma) or hIgA (Zymed, South San Francisco, CA).  Microspheres 
were incubated for one hour at room temperature.  As a control for non-specific 
antibody adsorption, separate aliquots of the microspheres were incubated with 
primary antibody not specific for the conjugated protein.  Microspheres were washed 3 
times with PBS, and resuspended to 5 mg/ml in a 1:50 dilution in PBS of PE-labeled 
goat-anti-mouse IgG (Molecular Probes).  Microspheres were incubated for one hour 
at room temperature, and then washed 3 times with PBS before analysis by flow 
cytometry. 
Each of the selected protein ligands could be conjugated to the surface of the 
PLGA/PEMA microspheres, as shown in Figure 2.8.  The presence of the ligand is 
indicated by the rightward shifts in the fluorescence histograms for microspheres 
incubated with antibodies specific for the particular ligand (solid fill).  Controls for 
nonspecific primary or secondary antibody adsorption to the microsphere surface 
(black lines) have nearly equal fluorescence intensity as microspheres not incubated 
with labeled antibodies at all (gray lines).  This suggests that the level of non-specific 
protein adsorption to the PLGA/PEMA microsphere surface is relatively low in 
comparison to the amount of protein that can be chemically conjugated via linkages to 
surface carboxylic acid groups. 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8.  Detection by immunocytometry of (A) HSA and (B) hIgA conjugated to 
PLGA/PEMA microspheres.  Histograms are of fluorescence intensity.  Gray line: 
microspheres before incubation with antibodies.  Black line: microspheres incubated 
with irrelevant primary antibody (control for non-specific antibody adsorption).  Solid 
fill: microspheres incubated with primary antibody specific for conjugated protein. 36 
 
2.5  Encapsulated FITC-BSA release assay 
  PLGA/PVA and PLGA/PEMA microspheres with encapsulated FITC-BSA 
were suspended in PBS at a concentration of 2.0 mg/ml and incubated at 37°C on an 
orbital shaker at 125 rpm.  To evaluate the effect of ligand conjugation on 
encapsulated protein release, PLGA/PEMA microspheres with OVA conjugated to the 
surface were included in this study.  At selected time points the microspheres were 
centrifuged at 10,000x g for 5 minutes.  Supernatant aliquots were removed from each 
sample, and replaced with an equal volume of fresh PBS.  Microspheres were 
resuspended and returned to the shaker.  Supernatant samples were stored at –80°C 
until analysis.  Sample fluorescence was measured on a Perkin Elmer LS 55 
luminescence spectrometer (Shelton, CT), with excitation and emission wavelengths 
set at 488 and 520 nm, respectively.    
  Changing from PVA to PEMA as the stabilizer during microsphere production 
did not significantly change the encapsulation efficiency of FITC-BSA (21.4% for 
PLGA/PVA vs. 24.9% for PLGA/PEMA).  Microspheres produced with each 
surfactant also displayed similar release profiles for encapsulated protein (Figure 2.9).  
Both sets of microspheres had an initial burst release of encapsulated protein lasting 
for approximately 2 days, followed by an extended period of slow protein release.  
PLGA/PEMA microspheres conjugated to protein ligands had lower overall levels of 
FITC-BSA release, due to loss of encapsulated protein during the ligand conjugation 
process.  In effect, the initial burst release of encapsulated protein for these 
microspheres took place during ligand conjugation, resulting in microspheres with 
lower, but still significant, levels of encapsulated protein.  
 37 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9.  Cumulative release of encapsulated FITC-BSA from PLGA microspheres 
during incubation in PBS at 37°C.  Data for PLGA/PEMA microspheres after 
conjugation protocol (open symbols) represented as percent of original (pre-
conjugation) protein loading.   = PLGA/PVA microspheres ¡ = PLGA/PEMA 
microspheres, before conjugation  = PLGA/PEMA microspheres, after conjugation 
to OVA.  Data are means of 3 separate samples for each group, and error bars indicate 
standard deviation. 
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2.6  Conjugated ligand release assay 
  PLGA/PEMA microspheres conjugated to 5-(aminoacetamido)fluorescein 
were suspended in PBS at 5 mg/ml and incubated at 37°C for various lengths of time.  
After incubation, microspheres were washed twice with fresh PBS, and resuspended.  
Retention of fluorescent ligand was measured by flow cytometry of microspheres.  
Total surface conjugated ligand was estimated by comparison of the fluorescence 
intensity of microsphere-ligand conjugates to fluorescent standard beads (Quantum™ 
26, Flow Cytometry Standards Corp., San Juan, PR). 
  Fluorescence intensity of PLGA/PEMA microspheres with bound fluorescent 
ligand was converted to ligand density by comparison to a standard curve relating 
mean fluorescence to molecules of equivalent soluble fluorochrome (MESF) of 
polystyrene calibration beads.  This comparison indicated that an average of 26,300 ± 
276 (mean ± standard deviation of 3 measurements) ligand molecules were conjugated 
per microsphere.  During incubation in PBS at 37°C the microspheres lost 
approximately 10% of the conjugated ligand within 3 days, at which point ligand 
release stopped (Figure 2.10).  Microsphere fluorescence remained constant from this 
point to the remainder of the incubation period of 40 days.  Supernatants of the 
incubation buffer were analyzed by fluorometry, and the presence of released ligand in 
the supernatant was consistent with the release profile of Figure 2.10.   
  
2.7  Summary of ligand conjugation to PLGA/PEMA microspheres 
  The experiments described in this chapter show that using PEMA as a 
surfactant to stabilize emulsions during the microsphere production process results in 
microspheres that have similar properties to microspheres made with PVA as the 
stabilizer.  The PLGA/PEMA microspheres enable ligand conjugation by 
carbodiimide cross-linking at a level similar to that achieved with carboxylated  39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10.  Retention of conjugated 5-(aminoacetamido)fluorescein at the surface of 
PLGA/PEMA microspheres.  Data are means of 3 separate samples, and error bars 
indicate standard deviation. 
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polystyrene microspheres that are currently used as model particles in applications 
where microspheres with surface ligands are desired.  Even though the PLGA/PEMA 
microspheres are biodegradable, the linkage between conjugated ligands and the 
microsphere surface remain stable for extended periods of time, allowing these 
microspheres to be used for targeting of specific cell types in drug delivery 
applications. 
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CHAPTER 3 
IN VITRO EVALUATION OF MICROSPHERE TARGETING BY SURFACE-
CONJUGATED LIGANDS 
 
3.1  Purpose 
The PLGA/PEMA microsphere formulation described in Chapter 2 enables the 
coupling of ligands to the microsphere surface.  A pair of in vitro model systems were 
developed to evaluate the effect of surface-bound ligands in targeting these 
microspheres to surfaces expressing specific receptors.  One model system is a matrix 
of agarose beads functionalized with receptors.  This system presents an environment 
of narrow pores for the microspheres to travel through, forcing close contact between 
microsphere-bound ligands and receptors immobilized on the agarose matrix.  The 
other system is a cell culture model, in which monolayers of Caco-2 intestinal 
epithelial cells are incubated with ligand-conjugated microspheres.  In this system, 
microspheres are floating freely in suspension, meaning that the nature of the 
microsphere interactions with the targeted surface (in this case the apical surface of the 
Caco-2 monolayer) is very different from that for the agarose matrix system. 
 
3.2  Retention of targeted microspheres on receptor-bearing agarose matrices 
  Columns packed with receptor-bearing agarose beads were prepared to 
investigate the effect of surface ligands on microsphere retention within the columns.  
A fraction of any microsphere type loaded onto the agarose matrix can be expected to 
be retained on the column due to simple steric effects.  An increase in retention of 
microspheres due to binding interactions between agarose-bound receptors and 
microsphere-conjugated ligands, however, would be an effective in vitro 
demonstration that the surface ligand capacity of PLGA/PEMA microspheres is 42 
 
sufficient to enable the targeting of microspheres to surfaces expressing appropriate 
receptors. 
 
3.2.1  Conjugation of ligands to PLGA/PEMA microspheres with encapsulated 
FITC-BSA for targeting to agarose-bound receptors 
PLGA/PEMA microspheres with encapsulated FITC-BSA were prepared as 
described in section 2.1.  Conjugation of streptavidin (Sigma), goat antibody specific 
for mouse IgG (Sigma), and BSA to the microspheres was performed according to the 
protocol described in section 2.3.   
 
3.2.2  Detection of conjugated ligands on microsphere surfaces 
Successful conjugation of the ligands to the microspheres was verified by flow 
cytometry (Figure 3.1).  Detection of goat-anti-mouse IgG and BSA was performed as 
described in section 2.4, using rabbit-anti-goat IgG (Zymed) and mouse-anti-BSA 
(Sigma) as primary antibodies, and PE-conjugated goat-rabbit-IgG and goat-anti-
mouse IgG (Molecular Probes), respectively, as the secondary antibodies.  For 
microspheres with streptavidin conjugated to the surface, aliquots were suspended at 5 
mg/ml in PBS with 5 µg/ml biotin-phycoerythrin conjugate (biotin-PE, Fluka, Buchs, 
Switzerland).  Microspheres were incubated for one hour, washed 3 times with PBS, 
and then analyzed by flow cytometry.  To measure non-specific binding of biotin-PE, 
control microspheres with BSA conjugated to the surface were also incubated with 
biotin-PE as described and analyzed by flow cytometry. 
Each of the selected protein ligands could be conjugated to the surface of the 
PLGA/PEMA microspheres, as shown in Figure 3.1.  The presence of the ligand is 
indicated by the rightward shifts in the fluorescence histograms for microspheres 
incubated with fluorescent labels specific for the particular ligand.  For ligands  43 
 
 
 
 
Figure 3.1. Detection of (A) goat-anti-mouse IgG, (B) BSA, and (C) streptavidin 
conjugated to the surface of PLGA/PEMA microspheres with encapsulated FITC-
BSA. Gray line: microspheres before incubation with fluorescent label.  Black line: 
controls for nonspecific binding of fluorescent label to microspheres.  Solid fill: 
microspheres incubated with fluorescent labels specific for conjugated protein. 44 
 
detected with labeled antibodies (Figure 3.1A, 3.1B), controls for nonspecific antibody 
adsorption to the microsphere surface (black lines) have nearly equal fluorescence 
intensity as microspheres not incubated with labeled antibodies at all (gray lines).  For 
microspheres conjugated to streptavidin (Figure 3.1C), the BSA-conjugated control 
for nonspecific adsorption of the biotin-PE label (black line) show a significant 
increase in fluorescence intensity compared to unlabeled control (gray line).  In this 
case, however, the fluorescence intensity of the streptavidin-conjugated microspheres 
is still one logarithm greater than that for the BSA-conjugated control.  
 
3.2.3  Conjugation of mouse IgG to agarose beads 
Fifteen ml of a 4% suspension of N-hydroxysuccinimidyl-agarose beads 
(Sigma) were washed with 30 ml of ice-cold Milli-Q water on a sintered glass filter.  
The beads were then transferred to a glass bottle and resuspended in 6 ml of a 1 mg/ml 
solution of mouse IgG (Rockland Immunochemical, Gilbertsville, PA) in 0.05 M 
sodium bicarbonate buffer (pH = 8.5).  The beads were incubated on an end-to-end 
mixer for 6 hours at 4°C.  After this incubation, 3.0 ml of 1 M ethanolamine in 
bicarbonate buffer was added to the beads, which were then incubated for 1 hour to 
quench any remaining unreacted sites on the beads.  The mouse IgG-conjugated 
agarose beads were then washed 5 times with cold PBS (15ml/wash), and then stored 
in PBS as a 4% suspension at 4°C until use. 
 
3.2.4 Retention of Microspheres on Agarose Columns 
1.5 ml of a 4% suspension of either agarose-biotin (Sigma) or mouse IgG-
agarose was added to glass columns (1 cm diameter) and allowed to settle overnight.  
After washing the column with 2 ml PBS, 1 ml of a 5 mg/ml suspension of 
microspheres conjugated to either BSA, streptavidin, or goat antibody specific for 45 
 
mouse IgG was added to the top of the agarose bed, followed by 20 ml PBS.  After the 
PBS was eluted, 15 ml of 6 M guanidine HCl (Sigma) pH adjusted to 7.5 was run 
through the column.  Eluate was collected in 1ml fractions, and the fluorescence 
intensity of each fraction was measured by fluorometry with excitation and emission 
wavelengths of 488 and 520 nm, respectively.  Fluorescence intensity of each fraction 
was converted to microsphere concentration by comparison to standard curves 
generated with suspensions of microspheres of each microsphere-ligand combination 
in both PBS and 6 M guanidine HCl. 
When ligand-conjugated microspheres were eluted from agarose columns, a 
significant quantity of the loaded microspheres were retained on the column, 
regardless of the particular microsphere ligand or agarose-bound receptor (Figures 3.2 
and 3.3).  The highest fraction of microspheres recovered in the eluate for any of the 
trials was approximately 55%.  The fraction of microspheres retained increases 
markedly, however, when the microsphere ligand is matched to the appropriate 
agarose-bound receptor molecule.  For the streptavidin-conjugated microspheres, total 
retention was roughly 50% on the agarose-mouse IgG column, but increased to 95% 
when the microspheres were introduced onto an agarose-biotin column (Figure 3.2).  
Microspheres with BSA conjugated to the surface were retained at a level of 
approximately 55% on the agarose-biotin matrix, indicating that the high level of 
retention for streptavidin-conjugated microspheres on the agarose-biotin column is due 
to specific interaction of microsphere-bound streptavidin with biotin coupled to the 
agarose matrix.  Similar results were obtained with microspheres conjugated to goat 
antibody specific for mouse IgG (Figure 3.3).  On the agarose-biotin matrix, 
approximately 80% of the microspheres were retained on the column, whereas nearly 
95% were retained on the agarose-mouse IgG column. 46 
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Figure 3.2.  Retention of streptavidin-conjugated microspheres on agarose columns.  
 = streptavidin-conjugated microspheres, agarose-biotin column.   = streptavidin-
conjugated microspheres, agarose-mouse IgG column.  = BSA-conjugated 
microspheres, agarose-biotin column.  Solid arrow: addition of microspheres to 
column.  Dotted arrow: switch in elution buffer to 6M guanidine HCl. 47 
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Figure 3.3.  Retention of goat-anti-mouse IgG-conjugated microspheres on agarose 
columns.  U = agarose-biotin column.  S = agarose-mouse IgG column.  Solid arrow: 
addition of microspheres to column.  Dotted arrow: switch in elution buffer to 6M 
guanidine HCl. 48 
 
Changing buffer from PBS to 6 M guanidine HCl during elution did not result 
in release of additional BSA- or streptavidin-conjugated microspheres from either the 
agarose-biotin or agarose-mouse IgG columns (Figure 3.2).  For the goat antibody-
conjugated microspheres, the change in buffer was followed by elution of 
approximately 10% of the microspheres from the agarose-mouse IgG column (Figure 
3.3).  These microspheres showed a similar two-step elution profile on the agarose-
biotin column, but the increase in elution rate started before the switch of elution 
buffer to 6M guanidine HCl, suggesting that it was caused by factors other than the 
change in elution buffer.   
 
3.3  Adhesion of targeted microspheres to Caco-2 cell monolayers 
  To model microsphere targeting to epithelial cells, monolayers of Caco-2 
intestinal epithelial cells were used.  The lectin UEA 1 binds to the apical surface of 
Caco-2 cell monolayers, and is used for labeling the apical surface of the monolayers 
[59], indicating that it is a suitable ligand for evaluating the ability of microsphere-
ligand conjugates to target surface receptors on monolayers of Caco-2 cells.  UEA 1 
binds to carbohydrates with terminal fucose residues, allowing the UEA 1 binding 
interaction with the cell surface to be inhibited through the addition of L-fucose to the 
incubation medium.  If microsphere targeting is being mediated by the intended 
ligand/receptor binding interaction, co-administration of the inhibitor with 
microspheres should negate targeting, so that the microsphere interaction with the 
targeted surface will be equivalent to that of control untargeted microspheres.  
 
3.3.1  Preparation of PLGA/PEMA microspheres for monolayer targeting 
  Conjugation of the lectin UEA 1 (Vector Laboratories, Burlingame, CA) to 
PLGA/PEMA microspheres with encapsulated FITC-BSA was performed according 49 
 
to the protocol described in section 2.3.  Preparation of control microspheres with 
encapsulated FITC-BSA and conjugated BSA was described in section 3.2.1.  
Successful conjugation of UEA 1 to the microspheres was verified by 
immunocytometry (Figure 3.4), performed as described in section 2.4, using rabbit-
anti-UEA 1 (Sigma) as the primary antibody and PE-conjugated goat-anti-rabbit IgG 
as the secondary antibody.  For the control sample of UEA 1 conjugated microspheres 
incubated with nonspecific antibody (Figure 3.4, black line), a slight increase in 
fluorescence is seen as compared to the other samples incubated with antibody 
nonspecific for the conjugated ligand (Figures 3.1A, 3.1B).  The nonspecific control 
antibody used with the UEA 1-conjugated microspheres was specific for BSA, making 
it likely that the observed slight increase in fluorescence is due to anti-BSA antibody 
binding to FITC-BSA entrapped near the surface of the microspheres.  This control is 
significant with regard to the BSA-conjugated microspheres (Figure 3.1B) as well, 
because it demonstrates that the level of anti-BSA antibody binding to FITC-BSA is 
relatively low.  The substantial rightward shift in fluorescence seen in Figure 3.1B is 
therefore due to antibody binding to surface-conjugated BSA, and not to entrapped 
FITC-BSA. 
 
3.3.2  Caco-2 cell culture 
The method for growing Caco-2 cells on porous filters has been described 
elsewhere[60,61].  Caco-2 intestinal epithelial cells of subclone BBe1 (ATCC, 
Rockville, MD) were propagated in 75 cm
2 flasks. The cells were grown in DMEM 
(4.5 g/l glucose, 10 mM HEPES), supplemented with 10% heat-inactivated FBS, 100 
U/ml penicillin, 100 µg/ml streptomycin, 1% nonessential amino acids, and 40 µg/ml 
human transferrin (all from Gibco, Grand Island, NY).  Cells were split 1/8 when they 
reached confluency (typically 6-7 days), and the medium was changed every 2 or 3  50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Detection of UEA 1 conjugated to the surface of PLGA/PEMA 
microspheres with encapsulated FITC-BSA. Gray line: microspheres before 
incubation with fluorescent label.  Black line: controls for nonspecific binding of 
fluorescent label to microspheres.  Solid fill: microspheres incubated with fluorescent 
labels specific for conjugated protein. 51 
 
days.  Polycarbonate Transwell filters (6.5 mm diameter, 3 µm pore size) (Corning 
Costar, Acton, MA) were inverted and placed in open Petri dishes.  The filters were 
coated with bovine collagen (Vitrogen®, Collagen Corporation, Palo Alto, CA), 15 µl 
per filter of a 2.8 mg/ml solution.  The filters were left in a sterile hood overnight to 
dry, and then placed in PBS until use. The collagen-coated filters were inverted in 
Petri dishes and seeded with 100 µl media containing 2.5x10
5 cells.  The Petri dishes 
were covered and incubated overnight at 37°C in a 5% CO2 incubator to allow cell 
attachment.  Filters were then returned to normal orientation in 24-well plates.  500 µl 
media was added to the lower (apical) chamber, and 125 µl media added to the upper 
(basolateral) chamber.  Medium was changed every two days, and cell monolayers 
were grown for 21 days before use in microsphere adhesion experiments.  Figure 3.5 
summarizes the process for seeding Caco-2 cells to the filters. 
Transepithelial electrical resistance of the Caco-2 monolayers was measured 
periodically with an EVOM™ voltmeter/ohmmeter (World Precision Instruments, 
Sarasota, FL).  For consistency, measurements were always taken immediately after 
the media in both chambers was replaced.  Resistance measurements indicated that 
Caco-2 cells grown on filters formed differentiated monolayers within 3 weeks after 
seeding.  Transepithelial electrical resistance reached approximately 400 Ohmcm
2 in 
this period (Figure 3.6), which is consistent with other reports for the resistance of 
well-differentiated monolayers of Caco-2 cells [60]. 
 
3.3.3  Microsphere Adhesion Study 
Microspheres with surface-conjugated BSA or UEA 1 were suspended in 
Caco-2 medium at 1 mg/ml.  L-fucose (Sigma) was added to an aliquot of the UEA 1-
conjugated microsphere suspension to a concentration of 500 mM, to inhibit lectin-
specific binding of microspheres to the Caco-2 monolayers.  600 µl aliquots of  52 
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Figure 3.6.  Transepithelial electrical resistance measurements for Caco-2 cells grown 
on Transwell™ filters.  ¡ = Filters with cells.   = Unseeded filters.  Data are means 
± standard deviations of individual measurements on filters at each time point (n = 4 
filters for unseeded filters, n = 12 for seeded filters). 54 
 
the microsphere suspensions were added to 24-well plates.  Caco-2 monolayers on 
filters were placed in the wells, and 125 µl of fresh media was added to the basolateral 
chambers.  Plates were covered and incubated at 37°C in 5% CO2 for 1 hr.  After 
incubation, filters were transferred to new 24-well plates, and media in the basolateral 
chamber was removed.  Filters were moved to wells containing 500 µl 2% 
paraformaldehyde in PBS, and 125 µl of paraformaldehyde solution was added to 
basolateral chambers.  Filters were incubated in this fixative for 30 min, and then 
transferred to wells containing PBS.  Filters were cut out of their supports with a 
scalpel, and mounted on microscope slides in Vectashield with DAPI (Vector 
Laboratories) and sealed with a glass cover slip and clear nail polish. 
 
3.3.4 Microsphere Counting 
Cell monolayers were viewed with a Zeiss Axiovert 200 inverted microscope 
with fluorescent filters.  Monolayers were viewed with a 20X objective, and 5 digital 
images were captured for each filter.  Sample images are shown in Figure 3.7.  
Microspheres per unit area were determined for each filter by visual counting of 
microspheres in each image.  Monolayer filter order was randomized for both the 
image capture and microsphere counting steps, which were performed by operators 
unaware of which microsphere type each individual filter was incubated with. 
BSA-conjugated microspheres adhered to the Caco-2 monolayers at a density 
of 710 ±205 microspheres/mm
2 (mean ± SD for 3 filters) (Figure 3.8).  Microspheres 
with UEA 1 as the surface-bound ligand showed a two-fold increase in adherence 
density, at 1330 ±118 microspheres/mm
2.  Incubating the UEA 1-conjugated 
microspheres with monolayers in medium containing 500 mM L-fucose inhibitor 
negated the targeting effect of the ligand, as the adhesion density was reduced to 690 
±78 microspheres/mm
2.  This adhesion density is essentially equal to that of the BSA- 55 
 
 
 
 
 
 
 
 
 
Figure 3.7.  PLGA/PEMA microspheres (green) adhering to the apical surface of 
Caco-2 cell monolayers.  Cell nuclei are stained with DAPI (blue).  A: BSA-
conjugated microspheres.  B: UEA 1-conjugated microspheres.  C: UEA 1-conjugated 
microspheres with 500 mM L-fucose.56 
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Figure 3.8.  Effect of surface ligands on microsphere adhesion to Caco-2 monolayers.  
Data are means ± standard deviation for individual filters (3 filters per group, 5 images 
per filter).  p = 0.018 for two-tailed Student’s t test comparison of results for BSA and 
UEA 1-conjugated microspheres. 57 
 
conjugated microspheres, indicating that the observed increase in adhesion density for 
UEA 1-conjugated microspheres is due to specific interactions of the UEA 1 with 
receptors on the apical surface of the epithelial cell monolayers.  Repetition of the 
adhesion experiment with fresh Caco-2 monolayers gave similar results, in which the 
presence of UEA 1 on the microsphere surface doubled the adhesion density of the 
microspheres compared to microspheres with surface-conjugated BSA. 
 
3.4  Conversion of Caco-2 monolayers to M cells 
  Efforts to isolate and immortalize M cells have proven unsuccessful to date.  
Such a cell line would be of great utility for in vitro investigation of the mechanisms 
of pathogen invasion across the intestinal epithelium, as well as for the testing of 
potential oral vaccine formulations.  M cell isolation is a daunting task in part because 
M cells are present in such low numbers in the epithelium, and also because there is 
evidence that M cells are not truly a distinct cell type, but are simply regular epithelial 
cells expressing a different phenotype in response to factors in their immediate 
external environment [21,62,63].  In light of this, Kerneis and coworkers have 
developed an M cell model using monolayers of Caco-2 cells cocultured with mouse 
Peyer’s patch lymphocytes [59].  Caco-2 cells in this model display several features of 
M cells, including poorly organized microvilli at the apical brush border and the 
ability to transcytose microparticles.  In this model, lymphocytes migrate through the 
pores of the filter the Caco-2 cells are attached to in order to come into direct contact 
with the Caco-2 cells [59]. Caco-2 cell conversion can be achieved by coculture with 
mouse Peyer’s patch lymphocytes or cells of the human Raji B cell line, but not 
human Jurkat T cells [59].  This coculture model has been used by a number of groups 
[59,61,64-66], who report similar findings with regard to microparticle uptake.  This 
model provides an opportunity to evaluate potential targeting ligands for human M 58 
 
cells such as hIgA [67] and SLAA [40] for their ability to increase microsphere 
uptake. 
 
3.4.1  Coculture of Caco-2 monolayers with Raji B cells 
  Caco-2 cell monolayers were grown as described in section 3.3.2.  Raji B cells 
(ATCC) were cultured in T-175 flasks at 37°C in 5% CO2, suspended in RPMI 1640 
medium (ATCC) supplemented with 10% FBS.  For coculturing, Raji cells were 
suspended in DMEM identical to that described in section 3.3.2, except with a glucose 
concentration of 1.0 g/l (low glucose DMEM) [61].  Raji cells were suspended at 
densities of 2x10
6 and 2x10
7 cells/ml.  Caco-2 monolayers grown on filters for 20 
days were transferred to wells containing 500 µl low glucose DMEM, and 100 µl of 
the Raji cell suspension was added to the basolateral chambers to make cocultures 
with either 2x10
5 or 2x10
6 Raji cells/filter.  Control monolayers received 100 µl low 
glucose DMEM containing no Raji cells.  Cocultures were incubated for 2 days at 
37°C in 5% CO2 to allow for M cell conversion.   
   
3.4.2  Staining of monolayers 
  Two days after seeding the filters with Raji B cells, filters were removed from 
media and transferred to wash wells containing 500 µl cold PBS.  125 µl cold PBS 
was added to the basolateral chamber.  PBS was removed, and filters were transferred 
to fresh wells containing 500 µl 2% paraformaldehyde in PBS.  125 µl of the 
paraformaldehyde solution was added to the basolateral chamber.  Filters were fixed in 
the paraformaldehyde/PBS solution for 30 minutes, and then washed twice with fresh 
PBS as described above.  Filters were then transferred to wells containing 500 µl/well 
0.3% saponin (Sigma) and 0.1% BSA in PBS (permeabilization buffer).  125 µl 
permeabilization buffer was added to the basolateral chamber, and filters were 59 
 
incubated for 30 minutes.  Filters were then incubated for 15 minutes in 50 mM 
NH4Cl in PBS, and then washed once with PBS and once with permeabilization 
buffer.  The filters were then incubated in 16% goat serum (Gibco), 0.3% saponin in 
PBS (blocking buffer) for 30 minutes.  After blocking, the filters were excised from 
their supports with a razor blade and placed on microscope slides (monolayer facing 
up).  Filters were then incubated overnight in 25 µl blocking buffer containing 40 
µg/ml rhodamine-conjugated UEA 1 (Vector Laboratories) and either 20 µg/ml hIgA 
or 4 µg/ml mouse monoclonal anti-SLAA (clone KM231, Kamiya Biomedical, 
Seattle, WA).  After overnight incubation, the filters were washed 3 times with 
permeabilization buffer, and then incubated for 45 minutes in 25 µl/filter blocking 
buffer containing 1:25 diluted FITC-goat-anti-human IgA (hIgA stained filters) or 
FITC-goat-anti-mouse IgG (anti-SLAA stained filters).  Filters were then washed 3 
times with permeabilization buffer, mounted with Vectashield containing DAPI, and 
sealed with a glass cover slip and clear nail polish. 
  Stained filters were viewed on a Zeiss Axiovert 200 inverted microscope with 
fluorescent filters.  Cells in the Caco-2 monolayers stained unevenly with rhodamine-
UEA 1, with some cells brightly stained while others showed little if any rhodamine-
UEA 1 binding at all.  Monolayers not cocultured with Raji B cells did not bind hIgA 
(Figure 3.9).  SLAA expression showed an interesting pattern, with a small fraction of 
the cells staining brightly (Figures 3.10B and 3.11A).  Cells staining brightly for 
SLAA did not typically stain with rhodamine-UEA 1.  Coculture with 2x10
5 Raji 
cells/filter did not change the apical surface expression of SLAA (Figure 3.13B) or 
receptors for UEA 1 (Figures 3.12C and 3.13C) and hIgA (Figure 3.12B).  The 
absence of a change in Caco-2 apical expression of hIgA receptors or SLAA in 
response to coculture with Raji cells indicates that targeting these receptors would not 
increase microsphere uptake in this M cell model.  Coculture with 2x10
6 Raji  60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.  hIgA receptor expression on Caco-2 monolayers 21 days after culture.   
A: Staining of cell nuclei with DAPI.  B: Staining for hIgA receptors with FITC.   
C: Staining of Caco-2 apical surface with rhodamine-UEA 1.  D: Composite of figures 
A-C. 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  Siayl Lewis A antigen expression on Caco-2 monolayers 21 days after 
culture.  A: Staining of cell nuclei with DAPI.  B: Staining for sialyl Lewis A antigen 
with FITC.  C: Staining of Caco-2 apical surface with rhodamine-UEA 1.   
D: Composite of figures A-C. 62 
 
 
 
 
 
 
 
 
 
Figure 3.11.  Selective expression of sialyl Lewis A antigen on Caco-2 cell apical 
surfaces.  A: Staining for sialyl Lewis A with FITC.  B: Rhodamine-UEA 1 staining of 
Caco-2 apical surface.  C: Composite of A and B.  Most cells expressing sialyl Lewis 
A do not bind UEA 1. 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12.  hIgA receptor expression on Caco-2 monolayers after coculture with 
2x10
5 Raji B cells.  A: Staining of cell nuclei with DAPI.  B: Staining for hIgA 
receptors with FITC.  C: Staining of Caco-2 apical surface with rhodamine-UEA 1.  
D: Composite of figures A-C. 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13.  Sialyl Lewis A antigen expression on Caco-2 monolayers after coculture 
with 2x10
5 Raji B cells.  A: Staining of cell nuclei with DAPI.  B: Staining for sialyl 
Lewis A antigen with FITC.  C: Staining of Caco-2 apical surface with rhodamine-
UEA 1.  D: Composite of figures A-C. 65 
 
cells/filter led to significant breakdown of the monolayer.  Caco-2 cells detached from 
large regions on each filter (Figure 3.14).  Not surprisingly, monolayer electrical 
resistance also dropped sharply for filters with 2x10
6 Raji cells (Figure 3.15, 
triangles).  Electrical resistance also dropped for filters incubated with 2x10
5 Raji cells 
(Figure 3.15, squares), suggesting that damage to the monolayer was occurring but 
was not yet pronounced enough to be revealed by microscopy (Figures 3.12 and 3.13). 
 
3.4.3  Microsphere uptake experiments with cocultured monolayers 
  PLGA/PEMA microspheres with encapsulated FITC-BSA and surface-
conjugated hIgA and HSA were suspended at 2 mg/ml in HBSS.  An aliquot of the 
hIgA-conjugated microsphere suspension had free hIgA added to a concentration of 
0.5 mg/ml to inhibit potential interactions between hIgA-conjugated microspheres and 
cell apical surfaces.  Microsphere suspensions were transferred to wells of a 24-well 
plate, 600 µl/well.  Filters with Caco-2 monolayers cocultured for 2 days with 2x10
6 
Raji B cells per filter were washed with HBSS and transferred to the wells containing 
microsphere suspensions.  150 µl HBSS was added to the basolateral chamber of each 
filter.  Filters were incubated at 37°C on an orbital shaker at 125 rpm.  At selected 
time points up to 6 hours, 100 µl HBSS from the basolateral chamber of each filter 
was collected and replaced with an equal volume of fresh HBSS.  Basolateral fluid 
samples were then analyzed by flow cytometry to detect transcytosed microspheres.  
Each sample was run on the cytometer for a known length of time at the same flow 
rate, allowing for comparison of the different samples on a number of 
microspheres/unit volume basis. 
The extent of monolayer damage after coculture with Raji cells was not known 
at the time the uptake experiment was performed.  Clearly, with Caco-2 monolayers 
degraded as badly as Figure 3.14 indicates, transcytosis by M-like cells is impossible  66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14.  Degradation of Caco-2 monolayers after coculture with 2x10
6 Raji B 
cells.  A: Staining of cell nuclei with DAPI.  B: Staining for hIgA receptors with 
FITC.  C: Staining of Caco-2 apical surface with rhodamine-UEA 1.  D: Composite of 
figures A-C. 67 
 
 
 
 
 
 
 
 
 
 
Figure 3.15.  Effect of Raji B cells on electrical resistance of Caco-2 monolayers.   
Raji cells were seeded onto filters 20 days after Caco-2 cell seeding (arrow). 
¡ = Monolayers with no Raji cells.  = Monolayers seeded with 2x10
5 Raji cells. 
S = Monolayers seeded with 2x10
6 Raji cells.   = Control filters with no cells.  
Data are means ± standard deviations for individual measurements on filters at each 
time point (n = 4 filters for unseeded filters, n = 6 for each group of seeded filters). 
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to evaluate.  Targeting of microspheres with specific surface ligands would not be 
measurable even if there was evidence that the monolayers expressed hIgA receptors, 
which is shown in Figure 3.12 not to be the case.  Figure 3.16 shows the results of the 
microsphere transcytosis experiment.  Microspheres incubated with cocultured 
monolayers were found in the basolateral fluid, most likely due to ordinary diffusion 
through the pores of the exposed filters.  Monolayers not cocultured with Raji cells 
maintained high integrity, with very low levels of microsphere transcytosis, which is 
consistent with other microparticle uptake experiments [59,61].  Interestingly, the 
uptake curves obtained in this experiment are comparable with those of similar studies 
reported in the literature [59,61], despite the evident degradation of the monolayers. 
  
3.5  Summary of in vitro microsphere targeting experiments 
  The results of experiments with PLGA/PEMA microspheres in the in vitro 
systems described in this chapter show that the ligands conjugated to the microspheres 
affect the interactions of the microspheres with the targeted surfaces.  The model 
systems provide a controlled environment for evaluating these interactions, in which 
the observed increase in adhesion of the microspheres to targeted surfaces is clearly 
caused by specific ligand-receptor interactions.  Ligand density on the microspheres is 
sufficient to enable targeting both in systems where contact between microspheres and 
receptors is virtually guaranteed, as in the case of the agarose columns, as well as in 
the open environment of the Caco-2 monolayers in which microspheres are freely 
suspended in solution. 
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Figure 3.16.  Transcytosis of PLGA/PEMA microspheres across Caco-2 monolayers 
cocultured with 2x10
6 Raji B cells.   = HSA-conjugated microspheres.  ¡ = hIgA-
conjugated microspheres.   = hIgA-conjugated microspheres in 0.5 mg/ml hIgA.   
¯ = hIgA-conjugated microspheres on monolayers with no Raji cells. 
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CHAPTER 4 
M CELL TARGETED MICROSPHERES IN MOUSE MODELS  
 
4.1  Purpose 
The in vitro model systems used in Chapter 3 to evaluate the effect of surface-
conjugated ligands on microsphere behavior are simplifications of the environments 
these microspheres would encounter in vivo.  To evaluate the effectiveness of surface 
ligands in targeting PLGA/PEMA microspheres to specific cell types in vivo, 
microspheres with surface-bound UEA 1 were orally administered to mice.  UEA 1 
has been shown to bind selectively to mouse M cells but not regular enterocytes 
[36,68], making it a suitable molecule for use in targeting microspheres to this cell 
type.   
This chapter describes experiments using PLGA/PEMA microspheres with 
encapsulated protein to try to demonstrate targeting of these microspheres to M cells 
in mice.  Microspheres with encapsulated FITC-BSA were used in uptake studies to 
attempt to detect microspheres in selected immunological tissues after oral 
administration.  At selected time points after microsphere administration, mouse 
tissues were harvested and analyzed for the presence of microspheres.  In order to 
demonstrate that targeting of microspheres to tissues not only increases their adhesion 
or uptake but also leads to improved clinical responses, microspheres with 
encapsulated OVA were used in an attempt to elicit anti-OVA antibody responses in 
serum and mucosal secretions in response to oral administration of microspheres.  The 
goal of these experiments was to extend the results obtained in Chapter 3 to an in vivo 
environment, to show that conjugating an appropriate ligand to the surface of 
microspheres increases their uptake by the targeted M cells, and that the increase in 
uptake leads to improved immune responses. 71 
 
4.2  Uptake of orally administered microspheres with encapsulated FITC-BSA in 
mouse tissues 
  Microspheres with encapsulated fluorescent label were orally administered to 
mice in an attempt to track microsphere uptake by M cells and transit to 
immunological tissues.  Successful tracking of microsphere uptake would allow 
evaluation of the effect of microsphere-conjugated UEA 1 on microsphere uptake by 
M cells. 
 
4.2.1  Microsphere administration and tissue collection 
 PLGA/PEMA  microspheres  with  encapsulated FITC-BSA were suspended in 
0.2 M sodium bicarbonate buffer at 50 mg/ml.  Female BALB/c mice were fasted for 3 
hr, and then 250 µl of the microsphere suspension was administered by oral feeding 
needle.  Mice were sacrificed by CO2 inhalation at 1 and 4 days after microsphere 
administration.  The spleen and mesenteric lymph nodes (MLN) were immediately 
harvested from each mouse.  The small intestine was then washed with PBS to remove 
intestinal contents, and Peyer’s patches were collected.  Harvested tissues were 
disrupted on a metal sieve and passed through a 40 µm cell strainer to create single-
cell suspensions.  Splenocytes were incubated in ACK lysis buffer (Quality 
Biological, Gaithersburg, MD) for 5 minutes at 4°C to lyse red cells.  Cells were then 
centrifuged at 300x g for 5 minutes, and the supernatant was discarded.  All cells were 
then suspended in 1% paraformaldehyde and analyzed by flow cytometry.  
Microspheres incubated in bicarbonate buffer for 1 and 4 days were used as controls 
for identifying microspheres during cytometry of the mouse tissue samples.  Control 
tissues were harvested as described above from one mouse that did not receive a 
microsphere dose. 
 72 
 
4.2.2  Uptake study results 
  Microspheres incubated in bicarbonate buffer for 1 and 4 days had essentially 
equal fluorescence, as shown in Figure 4.1.  Data for 100,000 particles were collected 
on the cytometer for each tissue sample, which were then compared to the 
microsphere controls to determine the presence of microspheres in the samples.  
Figure 4.2 shows density plots of particle fluorescence vs. forward scatter for each of 
the tissue samples, as well as the microsphere controls.  Microspheres had a minimum 
fluorescence intensity value of 100, which was used as a threshold value for 
determining the number of microspheres present in the tissue samples.  Figure 4.2 
shows that none of the tissue samples indicated the presence of microspheres.  
Repetition of this experiment with microspheres that had UEA 1 conjugated to the 
surface (prepared in section 3.3.1) had the same result. 
 
4.3  Targeting of antigen-carrying microspheres to mouse M cells 
  To complement the uptake experiments described above, similar studies with 
antigen-encapsulated microspheres were performed.  Microspheres were delivered 
orally, and both systemic and mucosal antibody responses to the encapsulated antigen 
were evaluated. 
 
4.3.1  Production of PLGA/PEMA microspheres with encapsulated OVA for mouse 
M cell targeting 
  PLGA/PEMA microspheres with encapsulated OVA were generated by the 
method described in section 2.1, using 100 µl of a 50 mg/ml OVA solution during the 
primary emulsion step.  Microspheres had smooth, unbroken surfaces (Figure 4.3), and 
a mean diameter of 814 nm.  Conjugation of UEA 1 and BSA to the microspheres was  73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Fluorescence intensity of PLGA/PEMA microspheres with encapsulated 
FITC-BSA.  A: Microspheres incubated 1 day in 0.2 M sodium bicarbonate. 
B: Microspheres incubated 4 days in 0.2 M sodium bicarbonate. 74 
 
 
 
 
 
Figure 4.2.  Mouse tissues analyzed for microsphere uptake by flow cytometry.  Data 
are shown as density plots of fluorescence intensity vs. forward scatter.   75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.  PLGA/PEMA microspheres with encapsulated OVA.  A: Microsphere 
morphology.  B: Microsphere size distribution (n = 2107). 
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performed according to the protocol described in section 2.3.  During the ligand 
conjugation process, small aliquots of the microspheres were removed immediately 
before addition of UEA 1 or BSA.  These aliquots were incubated overnight in borate 
buffer without ligand, but otherwise were processed identically to the microspheres 
conjugated to UEA 1 and BSA.  These microspheres with no conjugated ligand were 
later used to determine the amount of encapsulated OVA lost during the conjugation 
process.  Successful conjugation of the ligands to the microspheres was verified by 
immunocytometry (Figure 4.4), performed as described for microspheres with 
encapsulated FITC-BSA and conjugated BSA and UEA 1 in sections 3.2.2 and 3.3.1, 
respectively. 
 
4.3.2  Determination of OVA loading level in microspheres 
  Total OVA loading of the microspheres before and after conjugation to UEA 1 
and BSA was determined by bicinchoninic acid assay (microBCA™, Pierce, 
Rockford, IL).  Microspheres were dissolved in 0.5 M NaOH at a concentration of 5 
mg/ml.  After microspheres were dissolved, the samples were neutralized with an 
equal volume of 0.45 M HCl in PBS.  The amount of acid added to neutralize the 
solutions was slightly less than the stoichiometric amount because the microspheres 
produce lactic and glycolic acid during degradation.  In addition, the assay is more 
compatible with slightly basic samples than slightly acidic ones.  A diluent solution 
for OVA standards was prepared in such a way as to match the processing of the 
microsphere samples as much as possible.  PLGA/PEMA microspheres with no 
encapsulated or conjugated proteins were dissolved in 0.5 M NaOH at a concentration 
of 5 mg/ml and then neutralized with an equal volume of 0.45 M HCl in PBS.  This 
neutralized solution of dissolved microspheres was then used to prepare OVA 
standards based on a 250 µg OVA/ml starting solution, serially diluted 1:2 down to  77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Detection of (A) UEA 1 and (B) BSA conjugated to the surface of 
PLGA/PEMA microspheres with encapsulated OVA.  Gray line: microspheres before 
incubation with antibodies.  Black line: microspheres incubated with irrelevant 
primary antibody (control for non-specific antibody adsorption).  Solid fill: 
microspheres incubated with primary antibody specific for conjugated protein. 78 
 
0.98 µg OVA/ml.  Samples and standards were applied in triplicate to 96-well plates, 
150 µl/well.  Assay working reagent was prepared according to manufacturer’s 
instructions, and 150 µl was added to each well.  Plates were covered and incubated at 
37°C for 2 hours.  After incubation the cover was removed, and optical density of each 
well at 562 nm was measured on a ThermoMax 96-well plate reader (Molecular 
Devices, Sunnyvale, CA).  Averages were calculated for the triplicate wells of each 
sample and standard.   
A plot of OVA concentration vs. optical density for the standards produced a 
linear standard curve.  Comparison of optical density values of microsphere samples to 
the standard curve indicated that the microspheres contained 13.7 µg OVA/mg 
microspheres before conjugation to UEA 1 and BSA.  Microspheres undergoing the 
conjugation protocol but not incubated with UEA 1 or BSA had their OVA loading 
reduced to 5.3 µg/mg microspheres, a loss of 61% of the original encapsulated protein.  
Microspheres with UEA 1 and BSA conjugated to the surface showed no detectable 
increase in total protein compared to the microspheres not incubated with protein 
during the ligand conjugation process. 
 
4.3.3  Immunization of mice with microspheres containing OVA 
 PLGA/PEMA  microspheres  with  encapsulated OVA and either UEA 1 or BSA 
conjugated to the surface as described in section 4.3.1 were suspended in 0.2 M 
sodium bicarbonate buffer to produce suspensions that contained a total of 400 µg/ml 
OVA encapsulated in microspheres.  Another suspension of UEA 1-conjugated 
microspheres was prepared in a solution of 500 mM L-fucose, 0.2 M sodium 
bicarbonate buffer.  Microsphere suspensions were administered by oral feeding 
needle, 500 µl/mouse, for a dose of 200 µg OVA in microspheres/mouse, with groups 
of 5 mice receiving each of the 3 microsphere suspensions.  Mice were female 79 
 
BALB/c, 10 weeks old at the time of feeding.  As a control to verify the 
immunogenicity of the OVA encapsulated inside the microspheres, another group of 5 
mice received microspheres by subcutaneous injection.  These microspheres had UEA 
1 conjugated to the surface, and were suspended in PBS to produce suspensions 
containing 200 µg/ml OVA in microspheres.  Mice receiving injections were each 
given 250 µl of this suspension, for an OVA dose of 50 µg encapsulated inside 
microspheres.  A final group of 5 mice received no immunization (naïve controls).  
Ten weeks after the initial dose, microsphere administration was repeated for the 3 
groups receiving microspheres orally.  The groups and administered microspheres are 
listed in Table 4.1. 
 
Table 4.1.  Summary of Immunizations with Targeted  
PLGA/PEMA Microspheres with Encapsulated OVA 
 
Group 
# 
Administration 
Route 
Microsphere 
Ligand 
500 mM 
L-fucose 
OVA Dose 
(µg) 
Booster at Week 
10 (µg OVA) 
1 Oral UEA  1  + 200  200 
2 Oral UEA  1  - 200  200 
3 Oral  BSA - 200  200 
4 Subcutaneous UEA  1  -  50  N/A 
5 None  N/A  - N/A  N/A 
 
4.3.4  Collection and processing of samples for ELISA 
  Mice were transferred to fresh individual cages, where they remained until 
they had dropped a sufficient quantity of feces (~100 mg), which was immediately 
collected into microcentrifuge tubes.  Mice were then anesthetized with isoflurane in 
an induction chamber, and anesthesia was maintained at 2.5% isoflurane in oxygen, 
administered by precision vaporizer.  Vaginal lavage was performed on each 80 
 
anesthetized mouse by introduction of 20 µl of PBS into the vagina with a blunt 
micropipette tip.  PBS was pipetted in and out of the vagina 20 times.  Lavage was 
repeated with 20 µl of fresh PBS, for a total of 40 µl lavage fluid per mouse.  Blood 
was then collected from the retro-orbital sinus by penetration with 50 µl glass 
capillary tubes.  One hundred microliters of blood was collected per mouse.  Mice 
were then removed from the vaporizer, and bleeding was stopped by application of 
gentle pressure with a gauze pad.  Mice were returned to cages when ambulatory.  Pre-
immune samples were collected before immunization, and then after immunization at 
regular intervals. 
  Blood and lavage fluids were stored overnight at 4°C.  These samples were 
then centrifuged at 10,000x g for 10 minutes at 4°C.  Serum and lavage supernatants 
were then collected from each sample and stored at –80°C until analyzed for 
antibodies by ELISA.  Feces samples were suspended at 10% w/v in protease inhibitor 
cocktail (Roche, Indianapolis, IN) in PBS, supplemented with 10 µg/ml pepstatin A 
(Sigma).  Soluble protein was extracted from the fecal pellets by heavy vortexing of 
the samples to break up the pellets.  Samples were then centrifuged at 10,000x g for 5 
minutes, and extracts were collected from the supernatant and stored at –80°C until 
analysis by ELISA.  
 
4.3.5  Measurement of anti-OVA antibodies by ELISA 
  Each well of an Immulon 4HBX 96-well plate (Dynex, Chantilly, VA) was 
coated with 100 µl of a 5 µg/ml solution of either OVA or UEA 1 in 0.05 M carbonate 
buffer, pH = 9.6, covered, and incubated overnight at 4°C.  The plate was then washed 
once with 0.05% Tween-20 in PBS (wash solution).  Then, the plate was blocked with 
300 µl/well of either 3% BSA in PBS (OVA-coated plates) or 3% BSA, 200 mM L-
fucose in PBS (UEA 1-coated plates) and incubated for 4 hours at room temperature.  81 
 
The L-fucose was added to inhibit binding of the lectin UEA 1 to carbohydrate 
residues on antibody molecules, which causes unacceptably high background readings 
for the plate.  After blocking, the plate was washed 4 times with wash solution.  
Samples (serum, lavage fluid, feces extract) were diluted in 0.05% BSA in PBS (for 
anti-OVA antibody detection) or 0.05% BSA, 200 mM L-fucose in PBS (for anti-UEA 
1 antibody detection) and applied in duplicate to wells, 100 µl/well.  Dilutions of 
samples were 1:5 for feces extracts, 1:50 for lavage fluid, and 1:100 for serum.  Plates 
were incubated overnight at 4°C.  After incubation, plates were washed 4 times with 
wash solution.  Alkaline phosphatase-conjugated goat-anti-mouse IgG and goat-anti 
mouse IgA (Zymed) were diluted 1:200 in 0.05% BSA in PBS (for OVA plates) or 
0.05% BSA, 200 mM L-fucose in PBS (for UEA 1 plates).  One hundred microliters 
of the appropriate enzyme-conjugated antibody solution was added to each well, and 
incubated for 1 hour at room temperature.  Plates were then washed 4 times with wash 
solution.  One hundred microliters of 1 mg/ml p-nitrophenyl phosphate substrate in 0.2 
M Tris buffer (Sigma) was added to each well.  Plates were incubated for 30 minutes 
at 37°C to allow for substrate conversion, and the reaction was then quenched by 
addition of 100 µl/well of 1 M NaOH.  Optical density of each well at 405 nm was 
then measured, and the average of the duplicate wells for each sample was calculated. 
  No antibody responses were detected in response to the initial dose of orally 
administered microspheres, as shown in Figure 4.5.  This figure shows that 7 weeks 
after immunization the ELISA results for samples from mice receiving microspheres 
orally are equivalent to those of unimmunized controls.  For mice receiving 
microspheres subcutaneously, serum IgG anti-OVA and anti-UEA 1 responses were 
observed, with 3 of the 5 mice producing serum samples giving OD values over 2.0 
for both OVA and UEA 1 antibodies.  The oral booster dose given at week 10 had no 
noticeable effect, as the ELISA results for samples collected at week 12 show no  82 
 
 
 
 
 
Figure 4.5.  ELISA results for mouse samples collected 7 weeks after immunization.  
A: Anti-OVA response.  B: Anti-UEA 1 response.  Data are means ± standard 
deviation for 5 mice in each experimental group. 
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increase in OD for orally immunized mice compared to naïve controls (Figure 4.6).  
At week 12, 4 of the 5 subcutaneously immunized mice generated strong serum IgG 
anti-OVA responses, and 3 of 5 had strong serum IgG anti-UEA 1 responses. 
 
4.3.6 High-dose immunization of mice with OVA encapsulated in PLGA/PEMA 
microspheres 
  With the immunization study with targeted microspheres showing no 
detectable antibody responses in any of the groups receiving microspheres orally, an 
attempt was made to determine the minimum dose of OVA-encapsulated microspheres 
required to produce detectable antibody responses.  Mice from the unimmunized 
control group of the initial immunization study described in section 4.3.3 were orally 
immunized with PLGA/PEMA microspheres containing OVA, but not conjugated to 
any surface ligands.  Individual mice received from 400 to 1200 µg of OVA in 
microspheres.  Mice received oral booster doses of the same microspheres 6 weeks 
after the initial dose, in an amount equal to one-half the initial dose (200 to 600 µg 
OVA).   
Figure 4.7 shows the results of ELISA assays on samples collected 5 and 10 
weeks after the initial immunization.  Serum samples showed no significant increase 
in OD compared to an unimmunized control.  The anti-OVA fecal IgA response is 
modest at best, with OD readings at week 12 that are slightly higher than the 
unimmunized control.  The intensity of this response does not correlate with the size 
of the administered OVA dose, however, making conclusions difficult to draw.  Anti-
OVA IgA in the vaginal lavage fluid was not detectable at week 5.  Lavage fluid could 
not be collected at week 12 due to an outbreak of mouse parvovirus (MPV) in the 
animal housing facility.  The effect this outbreak may have had on the study is unclear, 
but MPV is known to perturb immune system function [69].  No matter the effect of  84 
 
 
 
 
Figure 4.6. ELISA results for mouse samples collected 12 weeks after immunization.   
A: Anti-OVA response.  B: Anti-UEA 1 response.  Data are means ± standard 
deviation for 5 mice in each experimental group. 
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Figure 4.7.  Anti-OVA response to high doses of OVA encapsulated in PLGA/PEMA 
microspheres.  A: 5 weeks after immunization.  B: 10 weeks after immunization. 
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the viral outbreak, a minimum required dose of OVA in PLGA/PEMA microspheres 
should be determined with untargeted formulations before attempting to repeat the 
immunization experiment with UEA 1-conjugated microspheres. 
 
4.4  Conclusions for mouse M cell targeting studies 
  Neither the microsphere uptake or immunization studies described in this 
chapter produced interpretable results.  Flow cytometry did not reveal the presence of 
microspheres in the spleen, MLN, or Peyer’s patches of mice at 1 or 4 days after oral 
administration.  Mice orally immunized with up to a total of 1.8 mg OVA (initial + 
booster doses) in microspheres showed no serum or mucosal antibody responses.  
Targeting of smaller OVA doses in UEA 1-conjugated microspheres also failed to 
generate measurable antibody responses. 
  Using flow cytometry to detect microspheres in tissues after oral 
administration has been described previously [70].  In that instance, polystyrene 
microspheres were used, enabling tissues to be dissolved in a solution of 1% Triton X-
100 and 1% KOH.  Such conditions are not appropriate for PLGA microspheres, as 
the alkaline environment would lead to rapid microsphere degradation.  The 
incubation in Triton X-100/KOH is in effect a purification step, as it selectively 
eliminates cells from the samples and therefore increases the (low) probability that 
events detected by the flow cytometer will be microspheres.  For tissue samples with 
very low concentrations of microspheres such as the ones analyzed in uptake 
experiments, this purification may have made the difference between detecting a few 
rare fluorescent microspheres in the sample and not detecting any.  With the 
restrictions on sample handling to prevent PLGA microsphere degradation, it might be 
advisable to seek alternate, simpler methods to detect microsphere adhesion and 
uptake by M cells.  A possible technique would be to harvest sections of small 87 
 
intestine containing Peyer’s patches for fluorescent microscopy at selected time points 
after oral administration of microspheres.  This histological method would provide 
less quantitative data compared to flow cytometry, but would allow for direct 
visualization of the cells being targeted. 
  A number of reports describe the generation of systemic and mucosal antibody 
responses to OVA in orally administered PLGA microspheres [25-27].  These studies 
all use microspheres with no surface ligands.  Total OVA doses ranged from 600 µg 
[25] to 6 mg (3 mg initial dose, 3 mg booster at 4 weeks) [27].  Sample collection and 
ELISA methods were similar to those described in sections 4.3.4 and 4.3.5.  The 
observed responses were not strong, especially considering the amount of antigen 
delivered, but they were clearly detectable.  The robust serum IgG response to OVA in 
the group receiving microspheres by subcutaneous injection (Figures 4.5 and 4.6) 
shows that the OVA remains immunogenic through the encapsulation and ligand 
conjugation protocols.  If encapsulated OVA doses larger than those used in section 
4.3.6 are required in order to generate observable antibody responses, preparing 
sufficient amounts of UEA 1–conjugated microspheres for evaluating the ability of M 
cell targeting to increase the efficiency of oral antigen delivery will be a costly 
endeavor.   
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CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK  
 
5.1  Conclusions 
  Replacing PVA with PEMA during PLGA microsphere production resulted in 
microspheres with a substantially enhanced capacity for surface ligand conjugation by 
carbodiimide cross-linking.  Switching between the two surfactants had no significant 
effect on microsphere size or morphology.  Perhaps more importantly, the release 
kinetics of encapsulated protein are unchanged for PLGA/PEMA vs. PLGA/PVA 
microspheres. 
  The carboxylic acid groups are present on the surface of PLGA/PEMA 
microspheres at a similar density to that of the carboxylated polystyrene microspheres 
that are currently used as model particles for microsphere targeting experiments, as 
demonstrated by the comparable fluorescence intensities of the two microsphere types 
after conjugation to 5-(aminoacetamido)fluorescein (Figure 2.7).  Binding of this 
fluorescent ligand to the microspheres was due to covalent conjugation, not surface 
adsorption, as shown in Figure 2.6.  Microspheres of PLGA/PVA and  
PLGA-COOH/PVA showed only limited capacities for ligand conjugation.  For 
PLGA/PVA microspheres this result was expected, as there are no carboxylic acid 
groups available for ligand conjugation with this microsphere formulation.  The 
PLGA-COOH/PVA microspheres, however, have carboxylic acid groups at the end of 
PLGA polymer chains.  The low levels of ligand conjugation to these microspheres 
compared to PLGA/PEMA could be caused by blocking of available carboxylic acid 
groups by PVA at the microsphere surface.  Another possible explanation is that 
because carboxylic acid groups are present along the entire length of each PEMA 89 
 
molecule instead of only at the ends, there are simply more total carboxylic acid 
groups present in PLGA/PEMA microspheres as compared to PLGA-COOH/PVA. 
  The amide bonds formed between microspheres and conjugated ligands show 
excellent stability in aqueous solution, with approximately 90% of the conjugated 
ligand still present on the microsphere surface after over a month of incubation in 
buffered solution.  The stability of the microsphere-ligand linkage will enable 
successfully targeted microspheres to remain at the desired location for the full 
duration of payload release.  For applications in which the microsphere payload has 
undesirable side effects, such as targeting of chemotherapy drugs to tumors, this 
stability is especially desirable, as it will help to hold the microspheres at the desired 
location.  Interestingly, comparison of surface ligand (Figure 2.10) and encapsulated 
protein release (Figure 2.9) curves indicates that conjugated ligand remains at the 
microsphere surface even after release of encapsulated protein has ceased. 
  The microspheres released a significant amount of encapsulated protein during 
ligand conjugation.  Microspheres with encapsulated OVA that were conjugated to 
BSA and UEA 1 in section 4.3.1 lost 61% of their encapsulated protein during the 
conjugation process.  Microspheres with encapsulated FITC-BSA lost a similar 
fraction of their encapsulated protein during ligand conjugation (Figure 2.9, open 
symbols).  The conjugation protocol exposed the microspheres to aqueous buffer for 
approximately 20 hours, during which time the microspheres released encapsulated 
protein.  The conjugation process did not change the kinetics of payload release for the 
microspheres, as the difference in release profiles in Figure 2.9 for PLGA/PEMA 
microspheres with conjugated ligands versus those not exposed to the conjugation 
protocol is simply a shift of the release curve forward by 20 hours. 
  In addition to the model ligand 5-(aminoacetamido)fluorescein, which is a 
small molecule (MW = 404.4), macromolecules can also be conjugated to 90 
 
PLGA/PEMA microspheres, as evidenced by the variety of proteins coupled to the 
microspheres in Chapters 2 and 3.  The detection of these conjugated proteins with 
labeled antibodies shows that the three-dimensional structure of the ligands was 
maintained through the conjugation process, at least at the epitopes recognized by the 
antibodies.  As the binding activity of the ligands is dependent on their three-
dimensional structure, it is critical that the conjugation process changes ligand 
structure as little as possible.   
 The  in vitro systems used to evaluate microsphere targeting to receptor-bearing 
surfaces in Chapter 3 further demonstrated that the conjugated ligands retained their 
binding activity, and also were present at sufficient density to affect the way the 
microspheres interacted with the targeted surfaces.  When the microspheres were 
loaded onto agarose columns, a significant fraction of the microspheres was retained 
in the column, regardless of the particular combination of microsphere-coupled ligand 
and agarose-bound receptor.  This is not surprising, as the agarose beads form a tight 
matrix that could be expected to physically impede the flow of microspheres no matter 
the particular ligand/receptor pair being evaluated in a given trial.  The addition of 
denaturing 6 M guanidine HCl to the columns did not result in any additional elution 
of BSA-conjugated microspheres from the agarose-biotin column or streptavidin-
conjugated microspheres from the agarose-mouse IgG column.  This observation 
supports the explanation that much of the microsphere load placed on each column 
becomes physically trapped within the column, for any ligand/receptor combination 
being investigated. 
  By matching the ligand on the microspheres with the proper receptor on the 
agarose matrix, however, microsphere retention was increased, as demonstrated by the 
significant increase in the fraction of streptavidin-conjugated microspheres retained on 
an agarose-biotin column (Figure 3.2, open squares).  A similar increase in 91 
 
microsphere retention was seen on agarose-mouse IgG columns using microspheres 
conjugated to goat-anti-mouse IgG (Figure 3.3).  Antibodies have previously been 
generated for the purpose of targeting microspheres to specific cell types [54], 
suggesting that this is a reasonable model ligand/receptor binding pair which could 
later be substituted with microsphere-bound antibodies specific for clinically relevant 
receptor molecules.   
  Compared to the agarose columns, the experiments with Caco-2 cell 
monolayers provide a very different environment for evaluating the ability to target 
PLGA/PEMA microspheres to a selected surface.  Caco-2 monolayers have been 
incubated with ligand-bearing microspheres in other studies [17,52], with the result 
being increased association of the targeted microspheres with the monolayers as 
compared to untargeted microspheres.  In these studies, the monolayers were at the 
bottom of the incubation chambers, so that microspheres settling to the bottom of the 
chamber during incubation had extended direct contact with the monolayer surface.  In 
the system described in Chapter 3, the cell monolayer is inverted and suspended near 
the top of the incubation medium, so that the monolayer only encounters microspheres 
freely suspended in solution.  The results show that conjugating the ligand UEA 1 to 
the microsphere surface doubles the adhesion density of the microspheres to the apical 
surface of the Caco-2 cells (Figure 3.8).  This increase was due to specific interaction 
of the microsphere-bound lectin with receptors on the apical surface of the monolayer, 
as incubation of the lectin-bearing microspheres with the cells in the presence of the 
inhibitory sugar L-fucose reduced adhesion density to the same level as for BSA-
conjugated control microspheres.  This model system is a simplification of the 
intestinal environment in vivo, most notably in the absence of the continually 
renewing mucus layer present along the gastrointestinal tract, but it does demonstrate 92 
 
that microspheres freely suspended in solution can be targeted to epithelial cell 
surfaces with appropriate ligands. 
 
5.2  Recommendations for future work 
  The characterization of PLGA/PEMA microspheres presented in Chapter 2 
compares microspheres of PLGA/PEMA to those of PLGA/PVA.  In addition, the 
comparison of fluorescence intensity of PLGA/PEMA and carboxylated polystyrene 
microspheres indirectly indicates that they have similar densities of available surface 
carboxylic acid groups.  Direct methods for characterizing the density of surface 
functional groups, such as zeta potential measurements or X-ray photoelectron 
spectroscopy [14,50] would be of value.  Making changes in the PLGA/PEMA 
microsphere production process might result in a further increase in surface carboxylic 
acid group density, and direct analysis by the methods mentioned would enable this to 
be evaluated.   
These methods could also be used to investigate the effect of surfactants other 
than PEMA on microsphere properties.  That switching from PVA to PEMA resulted 
in such minor changes to the resulting microspheres (apart from the desired change in 
functional groups at the microsphere surface) suggests that other surfactants could be 
successfully used as well.  Other polymers with backbones of carbon-carbon bonds 
and hydrophilic side chains should effectively stabilize the emulsion during 
microsphere production, and by selection of a molecule with the appropriate side 
chains a variety of different hydrophilic functional groups could be incorporated into 
the microsphere surface.  In situations where cross-linking chemistries other than 
carbodiimide coupling are desired, microspheres made with the appropriate surfactant 
would provide the necessary functional groups for the selected conjugation method. 93 
 
  It is important to quantify the extent of ligand binding to the microspheres.  
The level of 5-(aminoacetamido)fluorescein conjugated to the PLGA/PEMA 
microspheres could be estimated by comparison to standard beads as analyzed by flow 
cytometry.  Detection of protein ligands by flow cytometry, however, while it 
provides clear evidence of the presence of the ligands on the microsphere surface, is 
not quantitative.  Many of the antibodies used for detection of the conjugated proteins 
are polyclonal, including the PE-labeled secondary antibodies.  Uncertainty about the 
nature of the interaction between these polyclonal antibodies and their antigens (such 
as the number of epitopes on each antigen molecule recognized by the polyclonal 
mixture) makes determination of the number of conjugated ligands from cytometer 
fluorescence intensities difficult.  Efforts to quantify the amount of protein conjugated 
to the microspheres with the microBCA total protein assay were not successful, 
because the amount of conjugated protein was below the detection limit of the assay.  
Other colorimetric protein assays have similar detection limits, so alternative methods 
are needed.  Flow cytometry could be used [71,72], with monoclonal primary and 
secondary antibodies in order to obtain reliable estimates of conjugated ligand levels. 
  Identifying a technique that will allow quantification of the extent of protein 
ligand conjugation to the PLGA/PEMA microspheres would be helpful in optimizing 
the conjugation protocol.  The protocol used for conjugating ligands to the  
microspheres was designed for carboxylated polystyrene microspheres.  Since it was 
not originally intended for degradable microspheres, or for microspheres carrying 
encapsulated drugs, the duration of the various incubation steps was set without regard 
for premature microsphere degradation or payload release.  The results described in 
Chapter 2 show that substantial amounts of encapsulated protein are released during 
the ligand conjugation process.  While the microspheres still retain significant 
amounts of encapsulated material, this loss of payload is wasteful, and could likely be 94 
 
moderated with simple changes to the conjugation protocol.  Incubation lengths are 
one process parameter worth investigating, as is the relative concentration of EDC, 
microspheres, and ligands.  Since microsphere degradation is accelerated in both 
acidic and alkaline environments, adjustment of the pH of the buffer solutions used 
during ligand concentration may also affect payload release during ligand conjugation.  
Many of the agents considered for delivery via microspheres have a very high 
monetary value, so efforts that lead to reduction in payload loss during ligand 
conjugation would be worthwhile. 
  Some changes to the conjugation protocol that reduce premature payload 
release (such as shortening incubation times) are likely to also reduce the extent of 
ligand conjugation.  A balance will need to be found between ligand conjugation and 
microsphere payload retention.  The necessary ligand surface density to achieve 
successful microsphere targeting will likely vary depending on the application.  In 
vitro models are able to show that PLGA/PEMA microspheres have sufficient surface 
ligand capacity to target them to surfaces, at least in carefully controlled systems.  
Conditions in vivo are far more complex, and cannot truly be duplicated in vitro.  The 
in vivo experiments summarized in Chapter 4 are inconclusive with regards to 
microsphere targeting to M cells.  As discussed in section 4.4, it may be valuable to 
begin with simpler in vivo microsphere uptake models than those used in Chapter 4.  
Before attempting to show increased uptake of targeted microspheres in distant tissues 
such as the spleen or MLN, visualizing Peyer’s patches by microscopy after 
microsphere administration would show if targeted microspheres are at least adhering 
to M cells at higher levels than untargeted ones. 
  PLGA microspheres with surface-conjugated ligands may be useful for 
applications other than targeted drug delivery.  Specifically, these microspheres could 
be used as scaffolds for tissue engineering.  Influencing cell attachment and growth on 95 
 
microspheres with surface ligands has been pursued with systems such as PLGA/PVA 
microspheres with adsorbed poly(lysine) [73] and poly(ethylene glycol-di-
methacrylate-co-hydroxyethyl methacrylate) microspheres conjugated to fibronectin 
and collagen by glutaraldehyde [74].  PLGA/PEMA microspheres could be used in 
similar ways, serving as a biodegradable scaffold to which ligands promoting cell 
attachment could be covalently conjugated.  Porous microspheres can be produced by 
addition of salts such as NaCl or CaCl2 to the inner aqueous phase during 
emulsification [75].  If PEMA is also added to the inner aqueous phase, these pores 
would then be lined with carboxylic acid groups through the same surfactant 
partitioning that leads to carboxylic acid groups at the microsphere surface when 
PEMA is used as the stabilizer during the second emulsification step.  Peptide 
sequences known to promote cell adhesion and aggregation such as RGD or YIGSR 
[76] could then be conjugated to microspheres, via the peptide N-terminus.  If linkage 
to the N-terminus is not suitable, the peptides could be produced with lysine residues 
at one end to provide alternate amines for carbodiimide conjugation.   
In addition to the conjugated cell attachment promoters, the microspheres 
could be produced with encapsulated growth factors, which would release over time 
and further promote cell growth onto and into the porous microspheres.  For this 
application, the ideal microsphere size is likely to be much larger than the ~ 1 µm 
spheres discussed in this dissertation.  Reducing the duration of the sonication steps or 
changing other process parameters would result in microspheres on the order of tens to 
hundreds of micrometers in diameter, which would be more appropriate for use as cell 
scaffolds.  By using PEMA that has already been conjugated to the desired peptides as 
the surfactant during microsphere formation, it may be possible to produce 
microspheres with the desired exposed peptides without the need for a separate 
conjugation step after the microspheres are formed.  This would offer the advantage of 96 
 
avoiding release of encapsulated agents during ligand conjugation, as the ligands 
would already be present as the microspheres are formed. 
As with previous formulations of PLGA microspheres, PLGA/PEMA 
microspheres can encapsulate an essentially unlimited number of different agents.  
Release rates can be tailored to a specific application through adjustment of the 
lactide:glycolide monomer ratio in the PLGA polymer, without affecting the ability to 
conjugate ligands to the microsphere surface.  The carboxylic acid groups 
incorporated into the microsphere surface provide a functional group capable of 
covalent coupling to a range of ligands.  This microsphere formulation provides a 
biodegradable system with great flexibility in the design of targeted drug delivery 
vehicles, providing an opportunity to increase the efficiency of drug delivery in a 
variety of different applications. 
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